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A B S T R A C T
The Schizophrenia International Research Society (SIRS) recently held its first North American congress, which
took place in Orlando, Florida from 10-14 April 2019. The overall theme of this year's congress was United in
Progress – with the aim of cultivating a collaborative effort towards advancing the field of schizophrenia re-
search. Student travel awardees provided reports of the oral sessions and concurrent symposia that took place
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Rapporteur reports during the congress. A collection of these reports is summarized and presented below and highlights the main
themes and topics that emerged during the congress. In summary, the congress covered a broad range of topics
relevant to the field of psychiatry today.
1. Introduction
The Schizophrenia International Research Society (SIRS) recently
held its first North American congress, which took place in Orlando,
Florida from 10-14 April 2019. The overall theme of this year's congress
was United in Progress – with the aim of cultivating a collaborative effort
towards advancing the field of schizophrenia research.
Judge Steven Leifman opened the congress with his keynote talk, in
which he called for an end to the criminalization of mental illness. He
highlighted the plight of individuals living with a serious mental illness
as well as their families and caregivers who are often forced to turn to
the criminal justice system for help, since the mental health system
have failed them. There were five plenary sessions during the congress,
which addressed the following topics: the effectiveness of cognitive
behavioral therapy, the use of stem cells to study schizophrenia, the
role played by gluten in the treatment of the illness, the importance of
mobile phones in patient care, schizophrenia as a disorder of the self,
and schizophrenia and substance use disorder.
Student travel awardees provided reports of the oral sessions and
concurrent symposia that took place during the congress. A collection of
these reports is summarized and presented below and highlights the
main themes and topics that emerged during the congress.
2. Environmental risk factors
The timing of trauma exposure featured in a number of the talks.
Michael Bloomfield (University College London, UK) discussed the
findings of a systematic review on the effects of developmental stress
and trauma on dopamine function. He proposed that divergent altera-
tions in the dopaminergic system occur depending on the timing and
nature of developmental exposure. He used positron emission tomo-
graphy (PET) to investigate the dopamine synthesis capacity in healthy
adults who have and who have not been exposed to psychosocial ad-
versity. The study findings suggest that developmental trauma exposure
may alter the dopaminergic function at several levels, which in turn
may impair a range of neurocognitive processes to induce vulnerability
to psychosis.
The importance of the timing of developmental trauma also featured
in other talks. Luis Alameda (Institute of Psychiatry, Psychology, &
Neuroscience at King's College London, UK) presented a study that
explored the association between specific adversity types, the timing of
exposure, and the main symptom dimensions in First Episode of
Psychosis (FEP). In this study childhood adversities were categorized
according to the timing of exposure: early<12 years, and late 12>18
years. While sexual abuse and neglect were associated to the positive
dimension, emotional abuse and bullying was associated to the de-
pressive dimension. The timing of exposure of sexual abuse or neglect
did not moderate its effect on the positive symptoms. However, only
bullying occurring late, and not early, was associated with the de-
pressive dimension. These results suggest specific associations between
different adversities and symptom domains, and adolescence seems to
be a specific critical period for the effects of bullying on depressive
symptoms in FEP. Anthony Grace (University of Pittsburgh, USA) dis-
cussed the work he had done on the effect of environmental stress in
animal models. He explained that stress is induces the loss of hippo-
campal parvalbumin (PV) interneurons and leads to an overactive do-
pamine system. In particular, the timing of exposure to environmental
stress is deemed important. Rats exposed to stress later in life did not
experience a schizophrenia-like state but instead show signs consistent
with depression. He suggests that in adulthood, the perineural nets
(PNN) protects PV interneurons and therefore stress experienced during
adulthood is associated with a different type of impairment. In another
animal study, Xiyu Zhu (University of Pittsburgh Department of
Neuroscience, USA) presented data on a rodent model, wherein rats
were exposed to either 10 sessions of foot-shock stress, 3 sessions of
restraint stress, or combined stressors, delivered either in pre-puberty
or in adulthood. Adolescence stress alone, in the absence of prenatal
methylazoxymethanol acetate (MAM), produced long-term dopamine
hyperactivity and schizophrenia-like behaviors. A distinct pattern of
response was observed when the stress exposure occurred during
adulthood, suggesting adolescence could be associated with greater
stress-sensitivity.
Urs Braun (Central Institute of Mental Health, Germany) high-
lighted the importance of the social environment when studying schi-
zophrenia. Adverse social environmental factors, such as an urban up-
bringing, ethnic minority background and low social status, affect the
Anterior Cingulate Cortex (ACC) circuits. However, exposure to re-
sources of resilience, such urban green space and physical activity, also
affect the ACC circuits. This is consistent with the idea of potential
neural resilience and risk effect converging on the same circuitry.
Sabina Berretta (McLean Hospital – Harvard Medical School), USA)
discussed the role of the amygdala in stress response and anxiety
symptoms in schizophrenia and bipolar disorder. When comparing
postmortem tissue samples from the amygdala across healthy donors,
donors with schizophrenia, and donors with bipolar disorder, soma-
tostatin-expressing neurons were decreased in the lateral nucleus in
both patient groups, with respect to healthy donors. This points to a
disruption of molecular factors involved in stress- and anxiety- related
symptoms in the amygdala of people with bipolar disorder and schi-
zophrenia.
Daphne Holt (Massachusetts general Hospital, USA) discussed a
study conducted in a student cohort. She proposed that there is a me-
chanistic pathway whereby early stress-induced abnormalities in the
functioning of the medial temporal lobe lead to misperceptions and
misinterpretations of sensory stimuli. This is based on a study, in non-
help-seeking college students with subclinical delusional beliefs, that
showed that emotional reactivity partially mediates the association
between childhood adversity and psychotic experiences.
The impact of gene-environment interactions featured in the talk of
Monica Aas (King's College, London, UK). She discussed the use of
polygenic risk score (PRS) to investigate gene-environment interactions
in patients with schizophrenia. She presented the findings of a study,
which suggest a history of childhood trauma and PRS together ex-
plained a larger portion of the variance in case-control classification
compared to either childhood trauma or PRS alone. This supports the
contribution of both genetic factors and childhood adversity experi-
ences in psychosis. She also presented findings from a study, which
explored the associations of hair cortisol levels, childhood trauma ex-
posure, and cognition in patients with schizophrenia (n=25) and bi-
polar disorder (n=35) relative to healthy controls (n=94). Higher
hair cortisol levels were observed in patients who reported childhood
trauma compared to healthy controls. In a preliminary analysis, mar-
ginal associations were also found between hair cortisol levels, global
assessment of functioning scores and cognition. This suggests that hy-
pothalamic-pituitary-adrenal axis dysregulation could help characterize
a subgroup of patients with schizophrenia and bipolar disorder who
experienced childhood maltreatment. In another talk she presented
results from an analysis of the relationship between telomere length
and childhood trauma exposure in patients with severe mental illnesses.
Compared to healthy controls, patients with schizophrenia or bipolar
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disorder had shorter telomere lengths. Telomere length was not asso-
ciated with brain volume or clinical features. However, a history of
childhood abuse was associated with shorter telomere length in the
patient sample.
Raquel Gur (University of Pennsylvania, USA) presented data from a
longitudinal study of participants enrolled in the Philadelphia
Neurodevelopment Cohort (n∼9500) who underwent clinical assess-
ment, neurocognitive testing, and a subsample neuroimaging (MRI) and
genomic assessments. Environmental factors assessed included neigh-
borhood characteristics (e.g. crime, household income, marriage status)
and a history of exposure to traumatic stressful events. In this study,
children at high-risk for psychosis who lived in an unfavorable en-
vironment had poorer cognitive performance compared to those living
in a favorable environment. Low brain volumes and activation to a
threat task predicted vulnerability and symptom persistence. There was
a significant interaction between genetic and environmental factors.
Golam Khandaker (University of Cambridge, UK) presented recent
work investigating the relationship between childhood infections, in-
telligence, and the risk of non-affective psychosis in adulthood. The
results suggest that early-childhood infection was associated with sub-
sequent lower IQ and increased risk of psychosis. The association be-
tween infection and psychosis was mediated and moderated by IQ, and
the associations were similar in the general population and in full-sib-
ling pairs discordant for exposure. He concluded that lower premorbid
intelligence in individuals may arise from unique environmental fac-
tors, such as early-childhood infection, and early-childhood infection
may increase the risk of non-affective psychosis, partly by interfering
with neurodevelopment and partly by exaggerating the effects of cog-
nitive vulnerability to psychosis.
Mary Clarke (Royal College of Surgeons) reported on the recent
findings in a Finish cohort suggesting that exposure to stress during
pregnancy, especially during late pregnancy, increase the risk of a
psychiatric disorder. Specific associations were observed with mood
and personality disorders. Interestingly, the odds of a personality dis-
order increased with the severity of stress exposure, suggesting a dose-
response association. Importantly, observed associations were not af-
fected by depression during pregnancy.
3. Substance abuse and smoking
The high incidence of tobacco smoking in schizophrenia patient
cohorts came under discussion. Faith Dickerson (Sheppard Pratt Health
System, USA) presented findings illustrating an association between
cigarette smoking and poorer overall cognitive functioning, a higher
incidence of suicide, and premature mortality in schizophrenia. She
argued that the evidence clearly contradicts the idea that smoking is
merely a means of self-medication. Instead, she advocates that smoking
cessation should be an important target when treating patients living
with schizophrenia. Robin Murray (King's College London, UK) re-
viewed the findings of a meta-analysis, which suggests that the pre-
valence of tobacco use in first episode patients is higher compared to
non-users and smoking is associated with an earlier age of illness onset.
He suggests that tobacco smoking may be a causative risk factor for
psychosis. The meta-analysis revealed that the effect of smoking is in-
dependent of cannabis use in first episode psychosis. He proposed that
smoking might be related to persistent activation of the dopamine
system.
Smoking cessation interventions came under the spotlight. Mary
Brunette (Dartmouth Medical School, USA) highlighted the importance
of web-based smoking cessation interventions for patients with schi-
zophrenia. Her findings suggest that brief, web-based interventions can
be as effective as in-person treatment interventions in terms of moti-
vating patients to stop smoking. However, intensive interventions may
be required in order to achieve long-term smoking cessation.
Nevertheless, she explained that web-based interventions could be of
particular value for patients who do not have access to conventional
smoking cessation interventions. Gail Daumit (John Hopkins University
School of Medicine, USA) and Eden Evins (Massachusetts General
Hospital, USA) are co-directing a randomized clinical trial of a tobacco
smoking cessation intervention for persons with serious mental illness
that incorporates behavioral counseling and cessation pharma-
cotherapy tailored to participants’ readiness to quit. The intervention
also includes weight management counseling and physical activity. She
explained that this type of approach is significant as it addresses mul-
tiple cardiovascular risk behaviors, in particular as weight gain is often
associated with smoking cessation in patients with serious mental ill-
nesses.
In addition to cigarette smoking, substance use was a topic that
featured prominently during the congress. Deepak D'Souza (Yale
University School of Medicine, USA) proposed that cannabinoid in-
duced acute and persistent psychosis (CIAPP) is a distinct subtype of
psychotic disorders. He based this on a prospective study, studying
hospitalized CIAPP cases with three control groups, including psychosis
unrelated to cannabis, cannabis use disorder, and healthy controls. He
found a distinct behavioral, cognitive, and electrophysiological profile
of CIAPP. Also, CIAPP patients had fewer residual symptoms with
shorter duration of psychosis compared to the psychosis without can-
nabis use group. Oliver Howes (King's College London, UK) investigated
the association between cannabinoid 1 receptor (CB1R) availability and
memory in first episode psychosis. He presented findings showing a
reduced CB1R availability in first episode psychosis, with hippocampus,
striatum, anterior cingulate and thalamus being most significant. He
found that in the FEP group there was a lower CB1R in the anterior
cingulate cortex (ACC), but a higher activation in the ACC during
memory encoding. He concluded that in untreated FEP there is reduced
CB1R availability, which is associated with altered cortical function
during memory encoding.
Melissa Weibell (Stavanger University Hospital, Norway) presented
outcome data from the Scandinavian early Treatment and Intervention
in Psychosis Study (TIPS). At 10-year follow-up, on motor speed and
verbal learning indices, patients who stopped using substances within
the first two years of follow-up, improved over time whereas non-users
and users did not. Within the stop- and episodic use groups, patients
with narrow schizophrenia diagnoses performed worse compared to
patients with other diagnoses on verbal learning and on the overall
composite neurocognitive index. Early cessation of substance use was
associated with less cognitive impairment and some improvement over
time on some cognitive measures, indicating a milder illness course and
superior cognitive reserves to draw from in recovering from psychosis.
However, the group with continued use had more severe positive and
depression symptoms. Musa Sami (Department of Psychiatry, King's
College London) presented work on the differences in psychotic ex-
periences between patients with a first episode of psychosis and con-
trols. The findings suggest that cases had more intoxication experiences
than controls. The extent of cannabis used predicted both euphoric-like
and psychotic-like experiences. However, euphoric or psychotic ex-
periences did not depend on the potency of the cannabis used.
Frederika Scheffler (Department of Psychiatry, Stellenbosch University,
South Africa) presented data on the differences in hippocampal sub-
fields volumes in first episode schizophrenia spectrum disorders. She
found a significant interaction effect for group by cannabis use. She
proposed that the volumetric difference between groups may be due to
inflammation or the compensatory changes in schizophrenia, given that
the subiculum is associated with the HPA axis and is involved in
memory as well as dopamine regulation. Rashmi Patel (King's College
London, UK) presented epidemiological data from the Electronic Health
Record from the South London and Maudsley NHS Foundation Trust. Of
the sample of 29,412 with a psychotic illness, 3657 patients had co-
morbid substance use, the majority being male. Unnatural deaths were
three times more common in the comorbid substance use group. He
stressed the need for addressing substance use in patients with psy-
chotic disorders. Marco Colizzi (Institute of Psychiatry, Psychology and
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Neuroscience, King's College London) presented a double blind rando-
mized control trial aimed at investigating in healthy subjects whether
altered striatal glutamate measures underlie the acute psychotomimetic
effects of intravenous delta 9 tetrahydrocannabinol (d9-THC), which is
the psychoactive compound of cannabis. Results showed that compared
to placebo, d9-THC increased glutamate+ glutamine metabolites
(Glx). He proposed that lower baseline Glx in the striatum may be a
marker for developing psychotic symptoms following exposure to can-
nabis.
Luccas Coutinho (Universidade Federal de Sao, Brazil) discussed age
of illness onset and cannabis use. He conducted a study including 175
patients with a first episode of psychosis. He found that 41.2% of the
sample reported cannabis use and approximately 50% had used can-
nabis before 16 years of age. The cannabis users had a lower mean age
of onset of psychosis. Deidre Anglin (The City College of New York,
USA) proposed that aberrant salience could partially explain the asso-
ciation between cannabis use and psychotic like experiences (PLE). She
presented findings revealing that frequent cannabis users had higher
PLEs and higher scores on the aberrant salience inventory (ASI).
Regression models and mediation analysis indicated that recent can-
nabis use and PLEs were significantly explained by ASI scores.
4. Mental health in children and adolescents
A better understanding of the risk factors for psychosis in adoles-
cents and children could lead to more effective early intervention
programs. Maija Lindgren (National Institute for Health and Welfare,
Finland) suggests that psychosis risk symptoms in adolescents are good
predictors of persistent psychiatric service use. This is based on the
findings of a study that included 715 non-psychotic adolescents (be-
tween the ages of 15-18 years). The findings revealed that psychosis
risk symptoms (positive, negative, disorganized and general symptom
domains) are predictors of continued service-use, even when baseline
psychiatric diagnoses and the development of psychosis at follow-up
were accounted for. This suggests that even though psychosis risk
symptoms are not always indicative of psychopathology, they may be
useful for predicting the need for persistent psychiatric care.
Lauren Moran (McLean Hospital/Harvard Medical School, USA)
highlighted the potential risks associated with prescription ampheta-
mine use in the treatment of adolescents and young adults with
Attention Deficit Hyperactivity Disorder (ADHD). Her findings indicate
that amphetamine, in comparison to methylphenidate, is associated
with an increased risk of treatment-emergent psychosis in young people
with ADHD.
Gregory Strauss (University of Georgia, USA) compared patients
with schizophrenia with clinically high-risk youth to determine if re-
ward processing impairments, known to be assoicated with avolition,
are present in both groups. The findings point to impaired avolition in
both groups. However, in the high risk group the hedonic response was
most important, while value representation was most central in the
chronic group. He proposed that different reward processing domains
are more prominent during different phases of the illness.
Benjamin Perry (University of Cambridge, UK) presented findings
suggesting that a genetic predisposition for Type 2 Diabetes Mellitus
(T2DM) is longitudinally associated with a risk for psychosis. However,
it was not found to be a risk factor for depression. His findings are based
on a large epidemiological study including more than 4000 partici-
pants. He suggests that minor genetic variations, which predispose in-
dividuals to metabolic alterations during childhood, may over time
increase the risk for diabetes and psychosis.
Paul Allen (University of Roehampton and King's College London,
UK) presented a study that compared clinical high-risk (CHR) in-
dividuals to healthy controls, to determine if elevated glutamatergic
levels are associated with hippocampal dysfunction. They found a po-
sitive relationship between glutamatergic metabolite levels (Glx: glu-
tamate and glutamine) and task-related activation in the hippocampus
and dorsal striatum in controls and a negative relationship in CHR in-
dividuals. It was emphasized that this finding supports existing animal
models, suggesting that there is an association between increases in
hippocampal glutamatergic metabolite levels and reduced hippocampal
function during the development of psychosis.
Alison Yung (University of Melbourne, Australia) presented findings
from a study comparing individuals at ultra high risk for psychosis with
and without persistent negative symptoms. She found that at baseline
those with persistent negative symptoms were more likely to have poor
premorbid social adjustment, a history of childhood neglect, and im-
pairment in certain cognitive domains. At follow-up, those with per-
sistent negative symptoms were also more likely to have impaired
psychosocial functioning and poorer speed of processing.
The importance of studying genetic liability for schizophrenia in
adolescents and children came under discussion. Lotta-Katrin Pries
(Maastricht University Medical Centre, Netherlands) proposed that a
polygenic risk for schizophrenia moderate the relationship between
childhood adversity and psychotic-like experiences. This is based on the
findings of a general population twin cohort study including adoles-
cents and young adults. The study showed that the interaction between
polygenic risk for schizophrenia and childhood adversity were sig-
nificant predictors of negative and positive affect, and subtle psychosis
expression. In addition, two presenters referred to a family history of
psychosis/schizophrenia in their respective talks, which is a proxy for
genetic liability. Nicole Karcher (Washington University School of
Medicine, USA) presented findings, from a population-based study
conducted in school-age children between the ages of 9 and 11 years,
highlighting predictors of psychotic-like experiences. She identified the
following predictors of psychotic-like experiences, namely a family
history of psychosis, impaired cognitive functioning as well as inter-
nalizing symptoms. Psychotic-like experiences were also related to
impaired connectivity within certain neural networks, even when
controlling for the abovementioned predictors. Ditte Ellersgaard
(Mental Health Centre Copenhagen, Denmark) discussed the findings of
a study assessing psychotic-like experiences in children as young as 7
years of age, with a family history of psychotic disorders. Children with
a family history of schizophrenia had the highest incidence of psy-
chotic-like experiences, followed by those with a family history of bi-
polar disorder.
Suicidal behavior in children and adolescents featured in two talks.
Patricia Graham (The Institute of Living/Hartford Healthcare
Behavioral Health Network) emphasized the importance of suicide risk
amongst adolescents reporting psychotic symptoms. She found that
approximately half of young people enrolled in day treatment program
for psychosis reported suicide ideation and past suicide attempts. She
proposed that in particular delusions, obsessive compulsive symptoms,
cognitive inflexibility, and feeling accepted are important suicide risk
factors to consider when treating adolescents. Martin K. Rimvall (Child
and Adolescent Mental Health Center, Mental Health Services, Capital
Region of Denmark, Denmark) suggests that persistent psychotic ex-
periences in childhood are important risk factors for suicidal behaviour
in adolescence. He based this on the findings of a large longitudinal
study assessing psychotic experiences in children at age of 11 and again
at 16 years.
5. Non-pharmacological interventions
Cognitive interventions prominently featured in a number of talks.
Heather A. Adams (Maryland Psychiatric Research Center, University of
Maryland School of Medicine, USA) presented findings from a study
which examined the efficacy of cognitive behaviour therapy for psy-
chosis (CBTp) in reducing distress secondary to symptoms, improving
functioning, and reducing overall symptoms associated with the illness
in a group of 53 inpatients who took part in weekly one-hour illness
education sessions. Study participants attended 71% of the offered
groups, and 84% showed moderate to high engagement. Distress and
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symptoms were reduced, and global functioning increased, from base-
line to post-treatment. Patients agreed that CBTp helped them to learn
skills aimed at improving their daily lives and reported overall sa-
tisfaction with the intervention. She highlighted that future CBT in-
terventions should prioritize reduction in distress secondary to symp-
toms and improvement in overall functioning. The application of
cognitive behavioral interventions, particularly with a chronically ill,
treatment resistant sample, was discussed. Eva Velthorst (Icahn School
of Medicine, Mount Sinai, USA) presented the findings of a randomized
control trial assessing the effectiveness of cognitive behavioral therapy
(CBT) in the treatment of social withdrawal and negative symptoms in
recent onset psychosis. Patients were randomized to either CBT with
treatment, or treatment as usual. Initially, the CBT group had greater
functional outcomes, however after six months there were no sig-
nificant between group differences. She suggests that with a longer
intervention period, in patients who are more stable, CBT could have a
more pronounced effect on social withdrawal and negative symptoms.
Jessica Wojtalik (University of Pittsburgh, USA) suggested that the
early use of cognitive enhancement therapy (CET) should be considered
when treating patients with recent onset schizophrenia. She discussed a
randomized control trial conducted in a sample of 106 individuals with
early course schizophrenia. Patients were randomized to either receive
CET or a comparison treatment (Enriched Supportive Therapy [EST]).
Those in the CET condition demonstrated greater gains in social cog-
nition and functioning over 18 months of treatment.
Karuna Subramaniam (University of California San Francisco, USA)
proposed that social cognitive training could be an effective treatment
option for impaired reward anticipation and goal-directed behaviors to
earn rewarding outcomes in patients with schizophrenia. She based this
on the findings of a double-blind randomized control trial where pa-
tients receiving intensive computerized social cognitive training were
compared with patients receiving cognitive training without the social
component. The group that received the social cognitive training had
significantly increased medial prefrontal activity post-intervention
which predicted and potentiated patients’ goal-directed rewarding
outcomes (i.e., their motivation and ability to earn more rewarding
outcomes). Related to the topic of social cognitive training, Deepa
Purushothaman (National Institute of Mental Health and
Neurosciences, India) presented results from a study, which examined
the effects of intranasal vasopressin on altruistic behaviour in schizo-
phrenia patients (n=30) compared to healthy controls (n=30). Both
groups participated in a “dictator game” which involves choosing
whether to keep (less altruistic) or share (more altruistic) money.
Patients further received a single dose of either intranasal vasopressin
or saline placebo in a double-blind counterbalanced design. Altruistic
behaviour was increased in patients treated with vasopressin, and a
lesser response was associated with higher childhood trauma exposure.
These findings suggest that vasopressin, known to play a role in social
cognition in schizophrenia, could also improve altruistic behaviour.
The association between cognitive behavioral intervention and
memory improvement was discussed by Martin Lepage (McGill
University, Canada). He presented a brief cognitive training, namely
Strategy for Semantic Association Memory training (SESAME), which
targets the self-initiation of semantic strategies in schizophrenia.
SESAME training led to significant improvements in memory perfor-
mance that were associated with increased activity in the left dorsal
lateral prefrontal cortex. These findings suggest the feasibility of a brief
cognitive intervention in patients with schizophrenia, which may ben-
efit from improved memory performance, particularly in patients with a
greater cortical “reserve”.
In addition to more conventional cognitive behavioural interven-
tions aimed at improving memory, Tobias Schwippel (University
Hospital Tuebingen, Germany) explored the use of transcranial direct
current stimulation (tDCS). He presented findings from a study, which
investigated the effects of right dorsolateral prefrontal cortex tDCS on
working memory performance in patients with schizophrenia (n=32).
In this study, 2mA (but not 1mA) tDCS improved working memory
accuracy during high cognitive load, and decreased reaction time
during mid- to high cognitive load, suggesting a shift towards increased
accuracy at the expense of longer reaction times. These findings support
the role of tDCS in improving cognitive functioning in schizophrenia.
However, higher current intensities might be required in this popula-
tion relative to healthy individuals. Other presentations on the use of
tDCS included that of Priscilla Oomen (UMC Groningen, Netherlands).
She described a randomized, double-blind, placebo-controlled trial that
compared twice-daily 20-minute treatments of 2mA tDCS for 5 days to
placebo in 54 patients with medication-resistant auditory hallucina-
tions. The trial showed no significant differences between active
treatment and placebo. However, this may be due to a small sample size
and the lack of clear data regarding the optimal electrode and wiring
placement. Amy Pinkham (The University of Texas at Dallas, USA)
proposed that an increase in neural activity in the right rostrolateral
prefrontal cortex could be key to improve introspective accuracy in
individuals living with schizophrenia. In an attempt to increase neural
activity in this region she used tDCS as an intervention. However it did
not lead to immediate significant behavioral improvement and instead
showed a potential delayed effect on introspective accuracy. She em-
phasized that more work is needed to determine if a longer duration of
stimulation will be more effective.
Susanna Konsztowicz (McGill University, Canada) discussed the
effectiveness of a cognitive-behavioral-based intervention in treating
illness engulfment. Illness engulfment is a process whereby an in-
dividual's concept of themselves becomes defined mainly by their ill-
ness. She conducted a trial whereby patients were either assigned to
treatment as usual or to a brief cognitive behavioral-based intervention.
The intervention reduced levels of illness engulfment and improved
self-esteem. However, it did not have an effect on depression and
quality of life.
Ian Ramsay (University of Minnesota, USA) discussed the neuro-
biological underpinnings of cognitive remediation. He presented find-
ings suggesting that improvement in cognitive functioning, with tar-
geted cognitive training, is associated with changes in cortical
thickness. He based this on a study comparing the effect of targeted
cognitive training in patients with recent onset schizophrenia (N=21)
and health controls (N=22). Those with reduced cortical thickness at
baseline were better able to make gains with the intervention. Changes
appeared in several brain regions over the course of treatment, espe-
cially in regions important for cognitive control and auditory proces-
sing. Results support the idea that cognitive training can be highly ef-
fective, but will be most effective when personalized and targeted to
functional and structural brain plasticity methods.
Keith Nuechterlein (University of California, Los Angeles, USA)
presented findings from a randomized controlled trial that compared
the effects of an individual placement and support plus workplace
fundamentals (IPS-WFM) intervention versus conventional vocational
rehabilitation plus social skills training on cognitive performance and
occupational/educational reintegration in first-episode schizophrenia.
In total, 69 patients took part in one of the two interventions and were
assessed on cognition and school/work recovery at baseline, 6 months,
and again at 18 months. IPS-WFM doubled the number of patients who
returned to work/school within 6 months. In the following 12 months,
92% of IPS-WFM participants remained in work/school. While baseline
cognitive deficits predicted work/school return at 6 months, neither
intervention improved cognitive performance over time. Supported
employment/education was identified as a powerful tool for helping
first-episode patients return to work/school. However, cognitive inter-
ventions are still needed and may be particularly useful to further im-
prove outcome.
Clinicians may find it difficult to decide on a specific type of re-
mediation that best suit patients’ individual needs. Studies assessing
predictors of response to cognitive remediation may be helpful in this
regard. Mike Best (Queen's University, Canada) proposed that specific
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types of cognitive remediation are associated with better outcomes than
others. He based this on the findings of a randomized controlled trial,
which compared perceptual and executive training in schizophrenia-
spectrum disorders. The study found that over time, executive training
was associated with greater cognitive improvement as well as func-
tional outcomes, in comparison to perceptual training. He noted that
executive training is potentially an important predictor of treatment
outcomes. Similarly, Matthew Kurtz (Wesleyan University, USA) stu-
died predictors of response to cognitive remediation in a secondary data
analysis of two RCTs. His findings suggest that baseline executive
functioning errors and digit span performance are good predictors of
cognitive outcomes in cognitive remediation for schizophrenia.
Interestingly, baseline symptoms were not predictors of response.
Inconsistent with his hypothesis, age at study entry did not predict the
degree of improvement in working memory outcomes across these two
RCTs. Lastly, signal detection analysis suggested that cognitive vari-
ables at study entry, rather than demographic, illness or symptom
variables were most effective at accurately predicting cognitive im-
provers and non-improvers after CR treatment. Lana Kambeitz-
Ilankovic (Ludwig-Maximilian University, Germany) suggests using
techniques, such as machine learning, to individualize patient treat-
ment. She presented findings from a study that showed that machine
learning, using structural neuroimaging data, can accurately predict
which patients with schizophrenia are more likely to show improved
functional outcomes following intensive computer-based neurocogni-
tive interventions.
In the future cognitive remediation interventions could take ad-
vantage of pupillometry. Jimmy Choi (Olin Neuropsychiatry Research
Center, USA) highlighted the benefits of pupillometry-based cognitive
training. Unlike conventional computerized cognitive training, pu-
pillometry-based cognitive training adjusts for difficulty level by taking
into account effort used and level of engagement on neurophysiologic
barometers. This type of cognitive training may be more useful than
other types of interventions.
6. Inflammation and immune system
The theme of inflammation and the blood-brain barrier featured in
the talks presented below. Michael Benros (Mental Health Centre
Copenhagen, Denmark) reviewed epidemiological findings, which
provide evidence for infections, autoimmunity and neuroinflammation
as risk factors for psychosis. He explained that individuals that have
autoimmune diseases with potential presence of brain-reactive anti-
bodies and that also acquire infections have a further increased risk of
psychosis, potentially due to disruption of the blood-brain barrier.
Moreover, meta-analysis of CSF studies have indicated that the integrity
of the blood-brain barrier is affected in individuals with psychosis.
Lastly, he highlighted results from a recent meta-analysis indicating
beneficial effect of anti-inflammatory agents in the treatment of psy-
chotic disorders; however, large-scale biomarker-based RCTs are still
lacking and needed to identify individual with psychosis that are more
likely to respond to anti-inflammatory treatment. Hannelore Ehrenreich
(Max Planck Institute of Experimental Medicine, Germany) showed that
functional autoantibodies against the N-methyl-D-aspartate-receptor
subunit NR1 (NMDAR1-AB) belong to the normal autoimmune re-
pertoire of mammals. She discussed prerequisites for symptomatic
consequences and gave examples of inducers of NMDAR1-AB formation
or boosting, ranging from infection to chronic life stress, e.g. as ex-
perienced upon migration. In situations of chronic life stress, these AB
may even have an antidepressant (ketamine-like) action. Matthew
Campbell (Trinity College Dublin, Ireland) emphasized the importance
of claudin-5 protein levels in schizophrenia. Post-mortem studies in
schizophrenia patients suggest a decrease in claudin-5 levels in the
frontal cortex, which may be related to a blood-brain barrier disruption.
He suggests that more attention should be paid to the role played by
claudin-5 and how to repair the intergrity of the blood-brain barrier.
Emily Severance (Conte Center for Schizophrenia Research at Johns
Hopkins, USA) pointed out that Inflammatory Bowel Disease, Irritable
Bowel Syndrome and Coeliac Disease are highly comorbid with psy-
chiatric comorbidities. She proposed that an imbalance of the micro-
biome in the gut could increase the risk for schizophrenia. She ex-
plained that blood-brain barrier impairment as well as blood-gut barrier
dysfunction is associated with increased levels of certain autoantibodies
in animal and human samples. Katherine Burdick (Brigham & Women's
Hospital, Harvard Medical School, USA) discussed research in-
vestigating cognition and inflammation. The study found that in-
flammation contributed significantly to adverse cognitive outcome in
patients with both bipolar disorder and schizophrenia. The effect was
also evident in remitted patients. Cognitive domains affected by in-
flammation include cognitive flexibility, reward processing, spatial
processing and social cognition. She suggests that inflammation is an
important predictor of cognitive impairment not only during active
phases of psychosis, but very importantly also in remitted patients. Outi
Mantere (McGill University, CAN) reported that insulin resistance was
associated with an activation of the peripheral immune system in pa-
tients with first-episode psychosis by applying gene expression analysis.
These findings may provide implications for add-on treatments to pre-
vent physical complications in psychosis. Jarno Honkanen (University
of Helsinki) discussed ongoing work examining the transcriptome of
both effector and regulatory T cells in a sample of 32 patients and 48
healthy controls. Preliminary results show potential differences in
variation between LPS treated and not treated levels of IL1B, in both
cases and controls. These findings may indicate a linkage between
peripheral immune system and psychosis. Jarmo Hietala (University of
Turku, Finland) presented work using the latest generation of translo-
cator protein (TSPO) ligands in a sample of 14 patients with first-epi-
sode non-affective and affective psychosis and 16 healthy controls. Glial
TSPO binding was lower in first-episode psychosis and also related to
serum cytokine levels. CCL-22 was considered to be of particular im-
portance, as it seems to be elevated in psychosis. Similarly, Simon
Cervenka (Karolinska Institutet, Sweden) presented an individual-par-
ticipant data meta-analysis of TSPO positron emission tomography
(PET) studies in schizophrenia. The data together with immune marker
analysis support aberrations in both central and peripheral immune cell
function in schizophrenia.
Tyler Lesh (University of California, Davis) talked about how animal
models can complement human studies and offer additional mechan-
istic insights. They reported that in humans, maternal infections during
gestation increase risk for schizophrenia and other psychiatric dis-
orders. Based on the maternal immune activation (MIA) model, they
sought to test the hypothesis that maternal immune response con-
tributes to changes in the developing brain and behavior of non-human
primate (NHP) offspring. Although no significant group by time inter-
actions were identified, a significant main effect of group was identified
in both white and gray cingulate cortex free water, with MIA-exposed
offspring showing higher free water. These data suggest that extra-
cellular free water values are increased in MIA-exposed offspring,
particularly in the cingulate cortex. These findings parallel human
studies identifying increased free water in patients with schizophrenia.
7. Disorder of the self
Lénie Torregrossa (Vanderbilt University, USA) discussed the idea of
schizophrenia as a disorder of the self where splitting of different psy-
chological functions, loss of unity of the self, dissociations, and anom-
alous sense of agency are prominent symptoms. Together with her
colleagues, she studied the quality of two internal signals, the heart
beat and emotional embodiment, in schizophrenia patients, hypothe-
sizing that such signals would be noisier in patients compared to
healthy controls. The study findings suggest that interoceptive accuracy
was reduced in patients compared to controls, even after controlling for
time perception, body mass index, resting heart rate, and heart rate
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variability. They also found evidence for a decreased quality in reported
bodily sensation of emotions. Together, these results suggest an in-
creased level of internal noise in people with schizophrenia.
Anne Giersch (INSERM French Medical Research Institute, France)
explored the possibility of an association between patients’ often frag-
mented experience of time and bodily self-disturbance in psychosis. She
found differences between patients and controls, when using sequential
effects and electroencephalogram (EEG). An abnormal sensitivity to
sub-threshold asynchronies were found in the patient group only.
Despite distinguishing events in time unconsciously, patients showed an
impairment in predicting sequences which could be related to problems
in producing coherent information sequences at the millisecond level.
Neeltje Van Haren (Erasmus Medical Centre, Rotterdam,
Netherlands) discussed a study that assessed the role of aberrant mul-
tisensory integration (body ownership) and sense of agency in the
manifestation of self-disturbances. The study used the rubber hand il-
lusion (RHI) paradigm. Patients with schizophrenia (N=54) had a
smaller increase in strength of the subjective illusion after synchronous
relative to asynchronous stroking compared to healthy controls
(N=56). Also, in the patient group, the subjective RHI correlated with
severity of delusions. Proprioceptive drift (estimation of the index
finger position) was not affected, thus suggesting selective alterations in
embodiment and prime-based agency inference processing in schizo-
phrenia. Furthermore, results suggest that both prime-based agency
processing and embodiment underly self-disturbances.
Steven Silverstein (Rutgers University Behavioural Health Care,
USA) proposed, in light of evidence for perceptual and cognitive as well
as body ownership disturbances in schizophrenia, the possibility of
integrating the established notion of schizophrenia as a neurocognitive
disorder with the emerging evidence for a disorder of self-experience.
He suggested that some of the symptoms experienced by patients with
schizophrenia, such as broadened representations of body parts and
lengthening of time intervals, may reflect an attempt to compensate for
the increased noise and reduced consistency of interoceptive signals. He
concluded by suggesting that body-ownership issues in schizophrenia
should be viewed from within the perspective of Information Theory.
8. Cognition and functionality
James Gold (University of Maryland, USA) examined the impact of
working memory deficits in schizophrenia. He found that patients,
compared to controls, had reaction times that were nearly three times
longer when they had to hold a single item in their working memory.
This suggests that patients focus too much attention on the single item
they have to remember, which impacts on the time they take to respond
to a second stimuli. He argues that this explains why some patients
living with schizophrenia may have slower reaction times when enga-
ging in complex, multi-tasking activities that require them to store in-
formation while performing another task. Relating to the topic of
memory impairment, Anne Marie Teti (Institute of Living at Hartford
Hospital, USA) presented research that compared time-based relative
memory versus events-based prospective memory across the course of
schizophrenia. Clinically high-risk (n=25), first-episode (n=20) and
chronic (n=35) patients showed time-based prospective memory im-
pairment compared to controls (n=29), while only chronic patients
showed impairment in events-based prospective memory. Attention
deficits also increased from high-risk to first-episode to chronic pa-
tients. The findings suggest that time-based prospective memory im-
pairments are evident in high-risk and first-episode patients and may
represent a promising target for compensatory interventions to improve
long-term functioning.
MacKenzie Jones (University of Miami, USA) found in both healthy
controls and in patients with schizophrenia that an overconfidence in
your ability to perform on a social cognitive task is not related to actual
task performance. Instead, a sense of confidence was related to higher
levels of self-reported depression in the patient group. This suggests
that patients’ current mood may be an important contributor to poor
social functioning.
Improving functional outcomes and community integration was an
important theme that emerged during the congress. Els van der Ven
(Columbia University, USA) discussed 1-year trajectories of social and
occupational functioning among a large cohort (n>600) of people with
recent-onset psychosis receiving early intervention services in the US.
Four distinct trajectory classes of social and occupational functioning
were identified. The converging (59.2%) group had disparate trajec-
tories (low occupational, higher social) which eventually converged.
The other groups had high-stable (14.8%), moderate-stable (14.7%)
and low-improving (11.4%) trajectories. She found that improvements
in symptoms were most noticeable in the first six months of enrolment.
In particular, a female gender, being employed or in school at enrol-
ment and private insurance status were associated with the most fa-
vorable trajectory of social and occupational functioning. Jonathan
Wynn (VA Greater Los Angeles Healthcare System UCLA, USA) dis-
cussed the role of motivation as a predictor of community integration at
baseline and 12 months later in homeless veterans with psychosis. He
emphasized the importance of interventions targeting motivational
challenges to improve community integration of homeless individuals
after they are housed. Philip Harvey (Leonard M Miller School of
Medicine, University of Miami, USA) reported on performance-based
functional capacity measures in patients with schizophrenia using the
Virtual Reality Functional Capacity Assessment Task (VRFCAT). The
results revealed that patients with higher scores on reduced emotional
experience were able to engage in socially relevant virtual reality si-
mulations, in that their performance was significantly poorer on social
relevant compared to solitary activities. The results pointed to the dif-
ferential validity of solitary compared to socially relevant virtual reality
simulations and their impact on patients who manifest social anhedonia
and amotivation.
9. Neurocognition
Alfredo Sklar (Western Psychiatric Hospital, USA) presented a study
investigating deficits in selective attention early in the disease course,
through neurophysiological evoked responses to identify the pattern of
cortical activity associated with those impairments through cortical
source localization of evoked responses. Results revealed a selective
attention deficit in first episode schizophrenia. Source localization
analyses revealed that different patterns of cortical activity were asso-
ciated with the impairment, with healthy controls showing more ac-
tivity in efficient, parallel search regions across tasks and first episode
patients showing more activity in inefficient, serial search mechanisms
in response to a minor attention related challenge. This suggests that
even during the early course of the illness, cognitive control mechan-
isms are disrupted.
Jun Miyata (Kyoto University, Japan) proposed the jumping to
conclusions (JTC) bias of patients with schizophrenia, which is related
to delusion, is associated with abnormal transition between brain states.
This is based on a study including resting state functional magnetic
resonance imaging data using Energy Landscape Analysis (ELA) of
networks of interest (NOIs). Results showed that low-energy, stable
brain states were characterized by either consistently deactivated or
consistently activated brain states of all NOIs, while high-energy, un-
stable brain states were characterized by activation and deactivation of
salience-related NOIs. Healthy participants showed significant correla-
tion between more conservative decision making and more frequent
transition between these two brain states. This relationship was broken
in schizophrenia patients, with near-trend level correlation between
more hasty decision making (JTC) and more frequent transition.
Ilvana Dzafic (Queensland Brain Institute, Australia) presented a
study examining regularity learning in the psychosis spectrum, ex-
tending into the healthy population, in both stable and changing con-
ditions. The study included a total of 66 participants, 22 of whom had
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schizophrenia, 22 of whom were healthy controls, and 22 of whom
were non-psychotic patients (i.e., had a different psychiatric disorder).
Both clinical groups were worse than controls in regularity learning, but
regularity learning was also associated with a continuous measure of
psychic experience administered across groups, suggesting psychic ex-
perience is the driving factor, rather than a categorical diagnosis.
Regularity learning errors and predictor error attenuation were related,
linking implicit and explicit regularity learning behavior. The findings
also revealed greater connectivity in the left primary auditory cortex in
schizophrenia, suggesting a compensatory role.
Kathryn Lewandowski (Harvard Medical School/McLean Hospital,
USA) reported on the findings from a study investigating the cognitive
profile, clinical symptom severity, community functioning and resting
state brain connectivity in patients with psychosis and healthy controls.
There was reduced network connectivity in frontoparietal and motor
networks in both cognitively intact and impaired patients compared to
controls. Furthermore, in the cognitively impaired group additional
connectivity reductions were identified in particular sub-networks. Her
work emphasizes the importance of studying the neurobiological cor-
relates of impaired cognitive functioning in psychosis.
Cassandra Wannan (University of Melbourne, Australia) presented a
study on the neural correlates of visuospatial associative memory per-
formance. It was found that in comparison to healthy controls, chronic
and first episode psychosis patients have impaired visuospatial asso-
ciative memory. In patients these impairments were related to hippo-
campal subfield volumes in the CA4/dentate gyrus and the stratum. The
same was not found in the controls. She proposed that specific hippo-
campal subfields, such as the hippocampal stratum layers and the
dentate gyrus, may be particularly sensitive to the effects of chronic
stress and inflammation.
Various other presenters implicated the important role played by
the hippocampus in schizophrenia. Alison Preston (University of Texas
at Austin, USA) discussed the neural mechanisms that mediate the ef-
fects of past experiences on future learning. Knowledge extraction oc-
curs by representing commonalities and differences between past and
present events to sustain flexibility and decision-making in new con-
texts. Such capabilities are enabled by memory integration, a process
through which related events become interconnected in the brain. She
used an associative memory inference task during functional magnetic
resonance imaging to study processes underlying learning and in-
ferential judgment. Patients with schizophrenia showed impaired per-
formance at the inference task, as well as, aberrant anterior hippo-
campal-posterior mPFC signaling. This suggests that hippocampal
novelty signaling may be critical for memory integration and may un-
derlie memory deficits in schizophrenia. Daniel Ragland (University of
California at Davis, USA) presented a model in which dorsolateral PFC
(dlPFC) and hippocampal deficits may be at the heart of relational
memory impairments in people with schizophrenia. He discussed a
study that found that individuals with schizophrenia can encode item-
specific information to support familiarity-based recognition, but are
disproportionately impaired in relational encoding and recollection,
which involve the functioning of medial temporal lobe and prefrontal
cortex. Similar abnormalities are observed in first episode psychosis and
individuals at high-risk for psychosis, suggesting that episodic memory
impairment predates disease onset. Suzanne Avery (Vanderbilt
University, USA) presented work on relational memory and hippo-
campal function in cohorts of early and chronic patients with schizo-
phrenia. Participants underwent a relational memory task during
functional magnetic resonance imaging. They were exposed to repeated
face and object images to study novelty response and habituation. Both
early and chronic schizophrenia patients showed impairments in rela-
tional memory ability compared to healthy individuals. Relational
memory impairments were associated with hippocampal habituation
deficits in both the early and chronic course of the illness. This
strengthens evidence supporting the role of the hippocampus in rela-
tional memory impairment in schizophrenia.
10. Neurobiology
Karen Tangmose (Copenhagen University, Denmark) proposed that
thalamic glutamate levels are involved in the neural coding of predic-
tion errors (the difference between what we expect and what actually
happens) in patients with schizophrenia. She based this on findings of a
study examining glutamatergic levels in the thalamus and its relation-
ship with striatal prediction error coding in a first episode treatment
naïve cohort. The study results suggest that there is a trend toward
higher glutamate levels in patients versus controls. Also, a negative
correlation was found between thalamic glutamate and prediction error
signal in patients only.
Abanti Tagore (University of Toronto, Canada) proposed that cor-
tical hypodopaminergia underlies cognitive impairment in schizo-
phrenia. She based this on a positron emission tomography (PET) study
examining the release of cortical dopamine during a cognitive challenge
in healthy controls (HC), people with first episode psychosis (FEP), and
participants at clinical high-risk for psychosis (CHR). Results revealed
that when comparing FEP and HC, the FEP group had significantly less
dopamine release than healthy controls in the anterior cingulate cortex
and a trend toward less dopamine release in the dorsolateral prefrontal
cortex, but there were no differences between groups when comparing
CHR and HC.
Daniel Lodge (UT Health San Antonio, USA) discussed the prospects
of targeting hippocampal interneurons as an early intervention ap-
proach for schizophrenia treatment. The experiments by his group in-
volved a developmental disruption model of schizophrenia with pre-
natal methylazoxymethanol acetate (MAM) rats that is known to
recapitulate some of the histological, neurophysiological and beha-
vioral alterations of the syndrome. He presented data that examined the
hypothesis that restoring GABAergic signaling would result in the
rescue of the phenotype in the MAM rat model. The findings revealed
an overexpression of the α5 GABA receptor subunit and was associated
with increased tonic GABA currents, decreased ventral hippocampal
activity, normalization of aberrant dopaminergic neuronal population
activity in the ventral tegmental area, and reversed the deficits in ex-
tracellular set shifting. This provided a proof of concept regarding the
underlying circuit level pathology in the MAM model in hippocampal
parvalbumin interneurons.
Zheng Li (National Institute of Mental Health, USA) presented on
the regulation of dendritic spine development during adolescence by
Dysbindin-1 gene. In a set of experiments she investigated dysbindin-1
null mutant mice and its influence on dendritic spine morphology, sy-
naptic transmission and spatial working memory. She found that the
mice had a decreased number of dendritic spines in adolescence but not
in adulthood. This was shown to be overexpression of surface dopamine
2 receptor (D2R), leading to internalization of GluN2B and reduction of
cAMP, which in turn inhibit spine maturation. The specificity of D2R
activation and GluN2B inhibition as the underlying mechanisms was
demonstrated with agonist Quinpirole and antagonist Ro25-6981 re-
spectively, demonstrating the endocytosis of GluN2B with D2R activa-
tion. The specificity of these effects in adolescence was demonstrated by
treating the mice with D2R antagonists in adolescence but not in
adulthood. This suggests that there is a critical window of intervention
in adolescence that could prevent cognitive dysfunction.
Min Tae Park (University of Western Ontario, Canada) reported on
the use of the previously validated MAGeT Brain algorithm to study the
hippocampal subfields in First-Episode Psychosis and whether anoma-
lies correlate with glutamate receptor density. Authors leveraged high
resolution 7T brain MR images, previously published atlases of the
serotonin receptor system, and gene expression data from the Allen
Human Brain Atlas to test for correlations between serotonin and glu-
tamate receptor genes. Results show selective reduction of the hippo-
campal subfields in early psychosis in line with previous findings, with
CA4-dentate gyrus demonstrating greatest reductions. Gene expression
analysis indicated 5-HTR1A and 5-HTR4 receptor subtypes as
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predictors of AMPA and NMDA expression. Volumetric differences in
the subfields correlated most strongly with 5-HT1A and 5-HT4 receptor
densities. Overall, results demonstrate glutamate-driven hippocampal
remodeling in FEP.
Laurence Coutellier (The Ohio State University) discussed how the
brain specific transcription factor Npas4 mostly expressed in excitatory
cells is associated with cognitive impairments, i.e., deficiency in npas4
leads to cognitive deficits. Npas4 regulates the adolescent development
of prefrontal PV system. Also, adolescent (but not adult) deletion of
Npas4, as well as specific deletion of Npas4 in parvalbumin inter-
neurons, lead to cognitive deficits. These data show that the brain
specific transcription factor Npas4 may be an important molecular
mediator of the effects of the developmental NMDA receptor hypo-
function on PV-I dysfunction, thereby contributing to cognitive deficits.
11. Imaging studies
The findings of studies using the ultra-high field 7-Tesla MRI were
presented in a number of talks. Lena Palaniyappan (University of
Western Ontario, Canada) presented findings from a study, which
aimed to explore the contribution of brain glutamate and glutathione
concentrations to the prediction of early treatment response in first-
episode schizophrenia patients (n=26). Low glutamate levels were
associated with poorer social and occupational functioning at baseline,
while higher baseline glutathione were associated with a decreased
time to respond to antipsychotic treatment. In particular, it took pa-
tients with high glutathione levels only four weeks to achieve a 50%
reduction in symptom severity, compared to nine weeks in patients
with low glutathione levels. These findings support the added value of
measuring glutathione levels for improved early prognostication and
tailoring of treatment in first-episode schizophrenia. Adrienne Lahti
(University of Alabama, Birmingham, USA) presented results from a
study, which sought to explore the relationship between cortical glu-
tamate/GABA levels, blood-oxygen level dependent response during a
cognitive task, and functional brain connectivity during resting state in
first-episode psychosis patients (n=21) compared to healthy controls
(n=21). In this study, glutamate levels were lower in patients versus
controls, and showed opposing associations with the blood-oxygen level
dependent response in the two groups. This suggests that the dynamics
of major neural networks disrupts the relationship between cortical
glutamate levels and the blood-oxygen level dependent response during
the resting state. Hilleke Pol (University Medial Centre Utrecht Brain
Centre, Netherlands) presented data on the relationship between brain
GABA/Cr concentrations and cognitive performance in schizophrenia
patients (n=17) compared to healthy controls (n=23). In this study,
medical prefrontal GABA concentrations were lower in patients com-
pared to controls, and associated with better cognitive functioning.
These findings support the notion that changes in brain metabolism,
including altered cortical GABA levels are associated with cognitive
performance in schizophrenia. Sophia Frangou (Icahn School of
Medicine at Mount Sinai, USA) presented data from a study, which
explored the use of ultra-high field brain imaging to detect intra-cor-
tical myelination abnormalities in recent-onset schizophrenia patients
(n=17) and healthy controls (n=22). In this study, patients showed
abnormal “flattening” of the myelin distribution curve, in frontal, vi-
sual, auditory and somatosensory areas The findings indicate that intra-
cortical myelin imaging can be used to identify regions showing evi-
dence of early neurodevelopmental abnormalities in cortical organiza-
tion.
Achim Burrer (University Hospital of Psychiatry, University of
Zurich, Switzerland) presented a study that investigated whether mo-
tivational deficit in healthy individuals with schizotypal personality
traits (SPT) and patients with first episode psychosis (FEP) are asso-
ciated with reduced striatal volume and reduced thickness of the or-
bitofrontal cortex (OFC). Results showed a negative association be-
tween apathy and lower volume of right nucleus accumbens and
putamen bilaterally in individuals with SPT. In patients with FEP,
apathy was negatively associated with reduced OFC thickness. No
structural associations were identified with diminished expressivity.
Thus, structural correlates of apathy could be observed in healthy in-
dividuals with high SPT, and in patients with first episode psychosis.
Gemma Modinos (Institute of Psychiatry, Psychology, &
Neuroscience at King's College London, UK) presented a multi-site case-
control meta-analysis of structural MRI scans in non-help seeking in-
dividuals with schizotypy, based on the notion of dimensional con-
tinuity on the psychosis-spectrum between the general population and
patients with psychosis. Results showed a significant reduced volume of
left putamen in high schizotypy compared to low schizotypy. The re-
sults support a profile of subcortical abnormalities involving the
striatum in healthy individuals with subclinical psychotic-like experi-
ences.
Philipp Homan (Feinstein Institute for Medical Research, USA)
proposed that alterations of certain connectome measures could be
implicated in cognitive deficits in individuals with schizophrenia. The
graph theoretical approach of cortical network mapping was applied to
diffusion weighted imaging and structural MRI data to derive measures
of network organization and network efficiency and a regression ana-
lysis was used to predict individual variation of higher cognitive and
social cognitive performance. The main findings revealed that impair-
ments specifically in reasoning capacity were significantly associated
with rich club organization in patients.
Vishnu Murty's (Temple University, USA) presented a study in-
vestigating the interaction between contextual information, episodic
memory and large-scale memory networks in first episode psychosis. In
this study patients showed a trend towards greater connectivity within
the anterior medial networks compared to controls, while completing a
resting-state scan. While there were no group differences with regard to
the posterior medial networks, the integrity of posterior medial net-
works predicted individual differences in the organization of verbal
learning. He concluded that interactions across large-scale memory
networks might influence the types of contextual information that pa-
tients used during verbal learning.
Lindsay Oliver (University of Toronto, Canada) presented a study
aimed at detecting functional connectivity in separate subnetworks
underlying the same complex social cognitive task in individuals with
schizophrenia spectrum disorders and healthy controls. The findings
revealed that in low performers, greater functional connectivity across
social cognitive subnetworks was associated with lower social cognitive
performance when compared to high performers across both patients
and controls. A combination of both upregulated and downregulated
mirroring, empathy, and mentalizing networks were related to better
social cognitive performance.
12. Big data
Bo Cao (University of Alberta, Canada) introduced the term ‘big
data’ as a relative term that can be differently defined dependent on
one's perspective (i.e. data volume, data variety or data velocity) or
one's intention of analyzing the data. He discussed his study, which
focused on identifying and predicting biomarkers in medication-naïve
individuals with first-episode schizophrenia and predicting individual
responses to antipsychotic treatment within the field of precision
medicine with the use of machine learning. The main findings of the
study were that the identification of patients (balanced accuracy:
78.6%) and the antipsychotic treatment response prediction were suc-
cessful (balanced accuracy: 82.5%) with using functional connectivity
data.
Jennifer Coughlin (John Hopkins Medicine, USA) discussed the
utility of imaging in psychiatric research – and PET imaging in parti-
cular. PET imaging may optimize diagnostic precision through the de-
velopment of novel radiotracers for targeting key proteins relevant to
psychosis. One of such new developments is [18F]FNDP, which binds
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soluble expoxide hydrolase. Other new radiotracers relevant to study of
neuroimmunity were also presented. She proposed incorporating PET
imaging in clinical research protocols that focus on studying the neu-
roimmune response in psychosis, which can run parallel to study of
biomarkers in blood or cerebrospinal fluid. She also emphasized a need
for a consortium platform to share PET data to move the field forward.
Another talk referring to the role played by consortia is that of Neda
Jahanshad (Keck School of Medicine, USA). She emphasized the main
goals of the Enhancing Neuro Imaging Genetics Through Meta Analysis
(ENIGMA) consortium, namely to overcome major shortcomings of
structural neuroimaging studies in schizophrenia, including incorrect or
lack of statistical correction and the lack of replication studies due to
the use of different scanners and underpowered candidate neuroima-
ging genetic studies. She mentioned that the ENIGMA Genome-wide
Association study (GWAS) of subcortical structures, with approximately
15,000 subjects, showed highly consistent and replicated data across
sites. She also referred to the fact that the latest GWAS resulted in
optimized replication data of structural cortical measures across the
whole human brain, including measures of surface area and cortical
thickness that allows one to study age effects across the lifespan.
However, challenges with the use of big data were also discussed. In
particular, the long duration of collaborative projects across many
different sites and the agreement on harmonized protocol steps. Ofer
Pasternak (Harvard Medical School, USA) proposed the development of
data harmonization to overcome some of these challenges. In parti-
cular, he discussed advanced diffusion MRI acquisition and analysis
methods based on Free-Water Imaging to improve specificity in a har-
monized schizophrenia diffusion tensor images (DTI) data set.
13. New paradigms of discovery
Roman Kotov (Stony Brook University, USA) discussed the value of
using a dimensional approach to diagnosing patients with psychotic
disorders. He discussed the usefulness of a hierarchical, multi-dimen-
sional framework of symptoms and traits, called the Hierarchical
Taxonomy of Psychopathology (HiTOP). HiTOP is a model that char-
acterizes psychopathology dimensionally rather than binary absent/
present states. According to this model schizophrenia can be categor-
ized into two distinct spectra, namely psychoticism and detachment
with various symptom dimensions falling under each spectra. He sug-
gests that this framework has greater validity and reliability than
conventional diagnostic manuals.
Brett Clementz (University of Georgia, USA) discussed the Bipolar-
Schizophrenia Network for Intermediate Phenotypes (B-SNIP) project,
which used biotypes to diagnose patients with schizophrenia. He ex-
plained that there are different levels of intrinsic activity across the
different biotypes, which is not evident when comparing patients across
diagnostic and statistical manual of mental disorders (DSM) categories.
His team furthermore found that by using the biotypes and deviations
in level of intrinsic neural activity they were able to accurately predict
which patients are more likely to respond to different treatment types.
In future, clinicians might find the use intrinsic neural activity useful as
a biomarker for differential treatment response. Similarly, Rebekah
Trotti (University of Georgia, USA) presented findings from the bipolar-
schizophrenia network on intermediate phenotypes (BSNIP) study in
which the authors compared emotional scene processing between
healthy controls (n=197) and patients classified across three biotypes,
i.e. those with 1) low cognitive control and low sensorimotor reactivity
(n=198), 2) low cognitive control and high sensorimotor reactivity
(n=176), and 3) high cognitive control and average sensorimotor re-
activity (n=243) using EEG. Principal component analysis identified
two components of interest, namely an occipital component involved in
early visual processing, and a later emotionally-driven central parietal
component. Patients in the first group (n=198) differed the most from
the other study groups on both components. These findings suggested
that the BSNIP biotypes may be a useful for distinguishing psychosis
patients in terms of emotional scene processing and may represent an
index of functional impairment.
Michael Kirschenbaum (Zucker Hillside Hospital, Psychiatry
Research, USA) studied Google search entries in people with first-epi-
sode psychosis. He found that the majority Google searches were not
related to mental health and of those that were related to mental health,
the searches often targeted delusion related content, illicit drugs, or
motivational deficits. He proposed that Google search content differs
from clinical intake documentation and suggests that online search
behavior can provide a unique source of patient information.
Emily Eisner (University of Manchester) presented results from a
pilot study that explored the feasibility, acceptability and validity of a
smartphone application (ExPRESS) used to assess early signs and basic
symptoms as putative predictors of psychosis relapse. Patients diag-
nosed with psychosis (n=18) used the application for six months,
during which they were prompted by the application to indicate their
mood, symptoms, and early signs of relapse. Over the course of the
study, participants completed 65% of the application assessments and
completion declined gradually over time. Greater depression and fear of
relapse at baseline was associated with decreased likelihood of com-
pleting the application. The application showed high acceptability and
good predictive validity in terms of predicting symptoms over a period
of three weeks. These findings indicated that app-based monitoring is a
feasible, acceptable and valid means of predicting and assessing relapse
that will decrease the burden on both patients and caregivers.
Robert W. Buchanan (University of Maryland School of Medicine,
USA) introduced the notion of identifying individuals with schizo-
phrenia spectrum disorders based on the neural strategy used to per-
form the ‘Imitate/Observe’ fMRI task, rather than based on their clinical
diagnosis. In this study, Ward's hierarchical clustering of fMRI data
during the social cognitive task was applied to characterize participants
into groups dependent on shared or similar neural patterns of neural
network activation. They were able to identify three clusters with dis-
tinct patterns of neural circuit engagement during the performance of
the Imitate/Observe task, which were not related to clinical diagnosis
or clinical site. There were significant differences in social cognitive and
neurocognitive test performance across the three clusters.
Aristotle Voineskos (Centre for Addiction and Mental Health,
Canada) presented findings from a multi-center prospective study,
which investigated the neural underpinnings of social processes in
schizophrenia spectrum disorders. Study measures included neuroi-
maging, cognitive assessment, and several behavioral tasks. The study
used a data-driven approach to identify functional MRI biomarkers of
social function and cognitive performance. The study also identified
three data-driven clusters of participants based on patterns of neural
activity during the facial imitate/observe functional MRI task, and in-
terestingly cluster membership was not related to schizophrenia diag-
nosis. Relating to the theme of neurobiological underpinnings of social
processes as relevant markers, Erin Dickie (University of Toronto,
Canada) discussed the advantages of using the personalized intrinsic
network topography (PINT) approach when studying potentially re-
levant biological markers in individuals with schizophrenia. She ap-
plied this newly developed toolbox to resting-state data collected as
part of the Social Processes Initiative in Neurobiology of the
Schizophrenia(s) SPINS study and other datasets on an individual level.
The main findings were that correlations between well-established
cortical networks and the striatum as well as the cerebellum were in-
creased in both patients and controls when using PINT compared to
group templates. When patients and healthy controls were compared,
statistically robust reduced and increased functional connectivity pat-
terns of cortical-subcortical connections were found. The PINT ap-
proach may be more useful than previous group-based approaches.
14. Treatment outcomes and clinical trials
Findings from the amisulpride and olanzapine followed by open-
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label treatment with clozapine in first-episode schizophrenia
(OPTiMISE) study were presented. Mark Weiser (Sheba Medical Center,
Israel) explained that individuals presenting with a first episode of
psychosis often respond well to antipsychotics but frequently experi-
ence a relapse, particularly when antipsychotics are discontinued. His
talk focused on the prediction of subsequent relapse among those who
met remission criteria during the OPTiMISE study. In multivariate
analyses, cannabis was the only statistically significant predictor of
relapse. He noted that this corresponds with findings from previous
studies showing that cannabis is an important relapse predictor given
that cannabis affects dopamine release, which is related to symptom
severity. However, he also raised the possibility that cannabis use may
be simply a marker of a more severe type of illness. Armida Mucci
(University of Campania L. Vanvitelli, Italy) focussed on the prevalence
and impact of persistent negative symptoms (not confounded by de-
pression or extrapyramidal symptoms) in the OPTiMISE sample.
Negative symptoms were associated with poor psychosocial func-
tioning. Persistent negative symptoms predicted the worse psychosocial
functioning at the end of all treatment phases and were the most re-
sistant to antipsychotic treatment including clozapine. Lone Baandrup
(Psychiatric Center Glostrup, Denmark) examined the psychometric
properties of the negative symptom sub-scale of the positive and ne-
gative syndrome scale (PANSS), using data from phase 1 of the
OPTiMISE study. Rasch models were used to investigate whether the
information kept in the seven negative symptom items was exhausted
by the sum across items. Based on the findings of the rasch analysis she
found that the negative symptom subscale did not possess the necessary
properties to be a valid rating scale: items were inconsistent and did not
allow calculation of sufficient individual scores containing complete
negative symptom information for each participant. In contrast, an in-
dividual item approach better fulfilled the criteria of the Rasch model:
the sum score for each negative symptom item across visits was a suf-
ficient measure of the latent initial value.
A number of presenters focused in their talks on predictors of
treatment outcome. Kate Merritt (Institute of Psychiatry, Psychology, &
Neuroscience, King's College London, UK) discussed the relationship
between symptomatic reduction and change in glutamate during initial
antipsychotic treatment using proton magnetic resonance spectroscopy.
The results revealed that the nature of the response to antipsychotic
medication could be related to the pattern of changes in glutamatergic
metabolite levels over the course of treatment, emphasizing the links
between treatment response and alterations in central glutamate func-
tion. Jennifer Barnett (Cambridge Cognition, UK) suggested that latent
inhibition, a learning phenomenon known to be disrupted in schizo-
phrenia, may be a potential biomarker for stratification in schizo-
phrenia drug development. Their study established a reliable measure
of latent inhibition and showed it could be modified by both pharma-
cological and clinically-relevant manipulations in healthy volunteers by
using double-blind crossover designs. Brian Miller (Augusta University,
USA) identified significant correlations between cytokine levels and
psychopathology scores in patients with schizophrenia using a meta-
analysis approach, which may benefit understanding and treatment of
schizophrenia. In particular, they suggest that these modest but sig-
nificant correlations are indicative of a biological gradient across the
disease course that should be further explored in relation to the un-
derlying pathophysiology of schizophrenia. Cameron Carter (UC Davis
Health System, Imaging Research Centre, USA) found that baseline
frontoparietal task-related activity significantly predicted clinical im-
provement after one year of treatment in patients with early psychosis.
He also indicated the potential utility of functional magnetic resonance
imaging in personalized medicine, as treating patients presenting with
low frontoparietal activation by specialized intervention may improve
outcome. Daniel Martins-De-Souza (University of Campinas, Brazil)
identified biomarkers predictive of response to medication in plasma
from patients before and after treatment with antipsychotics. They
sought to validate the main biological processes previously found
associated with schizophrenia, such as tripartite synapses, spliceo-
somas, myelination and alterations associated with energetic pathways,
as well as the role of the endocannabinoid system in glia.
The following talks highlighted the theme of recovery and relapse.
Sidhant Chopra (Brain and Mental Health Hub, Monash University,
Australia) discussed the protective effects of atypical antipsychotics on
grey matter decline in psychosis. The relationship between greater
volumetric increase in the pallidum and better symptomatic outcome
suggests a key role of this structure in mediating symptom recovery.
Jose Rubio (Northwell Health, USA) presented on the incidence rate
and risk factors of relapse in patients diagnosed with a schizophrenia
spectrum disorder on maintenance treatment with long acting in-
jectable antipsychotics, for whom treatment adherence was confirmed.
In a national cohort, the results revealed that over a follow-up period of
up to 20 years, almost one third of patients relapsed despite ongoing
antipsychotic treatment. Greater risk was observed for younger in-
dividuals and also for lower clinical stability achieved despite anti-
psychotic treatment.
Olivier Corbeil (Mental Health University Institute of Quebec,
Québec, Canada) examined the association between aripiprazole ex-
posure and problem gambling in patients treated for first-episode psy-
chosis. The results revealed that the use of aripiprazole was associated
with more than a 10-fold increased risk of problem gambling. These
findings highlight the need to systematically evaluate gambling history
in all first-episode patients at entrance in first-episode psychosis pro-
grams.
Ina Weiner (Tel-Aviv University) presented data on maturation-de-
pendent efficacy of an ultra-low dose (0.045mg/kg) of risperidone in
preventing structural brain and behavioral abnormalities in adult fe-
male and male rats prenatally exposed to polyinosinic-polycytidilic acid
(poly-I:C). Based on previously published trajectories of structural and
behavioral deficits in poly-I:C offspring of both sexes, RIS was given in
four different time-windows (TWs) between young adolescence and
young adulthood. Adult poly-I:C offspring of both sexes had smaller
hippocampus, striatum, and prefrontal cortex volumes and larger lat-
eral ventricles volumes, disrupted latent inhibition LI and excessive
response to amphetamine. In both sexes, RIS prevented both structural
and behavioral abnormalities when given at TWs prior to but not after
the emergence of behavioral abnormalities. Because behavioral ab-
normalities emerged later in females than males, RIS was effective
longer in females. These results demonstrated that prevention of be-
havioral abnormalities required reversal of structural deficits and that
efficacy of prevention is lost with maturation.
Amanda Lyall (Brigham & Women's Hospital, Harvard Medical
School) reported results from a clinical trial wherein participants were
scanned at treatment onset and then randomly assigned to 16 weeks of
treatment with either risperidone and omega-3 or risperidone and
placebo. Participants were also scanned at the end of the clinical trial.
Their results suggest that omega-3 supplementation may partially at-
tenuate risperidone treatment-related white matter alterations in pa-
tients with recent-onset psychosis.
Clinical trials on the efficacy of antipsychotic drugs in the treatment
of cognitive impairment associated with schizophrenia (CIAS) came
under discussion. Stephen Brannan (Karuna Pharmaceuticals, USA)
reported on lessons learned from Forum's two global, placebo-con-
trolled, Phase III trials in stable patients with Cognitive Impairment
Associated with Schizophrenia (CIAS). All treatment groups showed
improvement, including the Placebo group. The post hoc analyses re-
vealed the following. Firstly, learning effects can be sustained, it is not
easy to get to the “plateau” where learning ceases to increase between
testing (i.e. the frequency of testing may be a factor, regional differ-
ences add to the variance of a global program, differences in experience
in rating the outcome measures can be critical - raters should thus be
experienced, low enrolling sites add to the variance and harm potential
drug-placebo differences). Subjects who are substantially noncompliant
add to the variance. Increasing enrollment speed can have deleterious
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effects (i.e. subjects “stable” on two antipsychotics had much larger
placebo responses than those stable on one antipsychotic, subjects en-
rolled at the end of the study had substantially different responses than
those enrolled at the beginning of the study). Lastly, the impact of
which antipsychotic subjects were stable on played a role (i.e. the
greater the sedative properties, the less the cognitive benefit, antic-
holinergic properties-the greater the effect, the less the cognitive ben-
efit). Kiri Granger (Cambridge Cognition, UK) investigated individual-
level trajectories of cognitive performance among patients with schi-
zophrenia enrolled in a multi-national Phase II clinical trial. They
conducted a re-analysis of an existing trial on 463 patients with schi-
zophrenia. Participants completed two different neurocognitive test
batteries, the Cambridge Neuropsychological Test Automated Battery
(CANTAB) and the MATRICS Consensus Cognitive Battery (MCCB) at
four time points: screening, baseline, week 6 and 12. Individual level
trajectories of cognitive performance revealed that patients who per-
formed below the normative mean at screening, showed a consistent
improvement in their performance across the rest of the study, while
patients who perform in the healthy individual range did not improve.
John Hutchison (Autifony Therapeutics, UK) presented on AUT00206, a
novel drug that modulates Kv3.1 and Kv3.2 channels. In animal models,
it showed an increase of the activity of parvalbumin interneurons and a
rescue of cognitive function. The potential of AUT00206 has been
evaluated first in healthy volunteers (Phase 1a) and subsequently in
patients (Phase 1b). Potential effect of the drug on cognitive perfor-
mance was evaluated with the Cambridge Neuropsychological Test
Automated battery (CANTAB); potential effect on neural circuitry was
assessed from measurement of auditory-evoked potentials, including
the mismatch negativity (MNN) response. Phase 1a support the safety
and potential efficacy of AUT00206. The phase 1b is currently un-
derway to establish whether AUT00206 can positively impact cognitive
outcomes. Interestingly, Jack Cotter (Cambridge Cognition, UK) pre-
sented the findings of a systematic review of clinical trials published
between 2000 and 2019. The findings revealed that only 11.5% of pro-
cognitive pharmacotherapy trials conducted in patients with schizo-
phrenia required the presence of an objectively assessed cognitive
deficit as part of their patient eligibility criteria. This is important as
recent evidence has suggested that up to a quarter of patients exhibit
‘normal’ cognitive performance (relative to matched healthy controls),
and that these individuals are significantly less likely to exhibit changes
in cognition when participating in intervention trials. He suggested that
the exclusion of these patients, or at least the stratification of patients
based on cognitive performance at baseline, could provide additional
statistical power to observe pro-cognitive treatment effects in clinical
trials.
Gjessing Jensen Karsten (Mental Health Centre, Capital Region of
Denmark) discussed the Tolerability and Efficacy of Antipsychotics
(TEA) trial, which investigated the cardiometabolic effects of extended
release quetiapine versus aripiprazole in youth with first episode psy-
chosis in Denmark. The study found greater weight gain in the youth
randomized to quetiapine compared to the youth randomized to ar-
ipiprazole after 12 weeks of treatment. Aripiprazole also had a more
favorable profile in terms of several other cardiometabolic indicators,
including waist circumference, blood pressure, cholesterol, insulin in-
crease, and insulin resistance. Bjϕrn H. Ebdrup (University of
Copenhagen, Denmark) reviewed the treatment of antipsychotic-asso-
ciated obesity with the glucagon-like peptide-1 (GLP-1) receptor ago-
nist exenatide, an antidiabetic drug. The study randomized patients
with schizophrenia and obesity to exenatide or placebo. It was found
that exenatide was not associated with weight loss after 3 months but
was associated with subtle improvements in bone markers. In contrast,
a meta-analysis suggests that GLP-1 agonists are effective for anti-
psychotic-induced weight gain, especially in patients treated with clo-
zapine and olanzapine.
Marc-André Roy (Université Laval, Canada) presented a retro-
spective cohort analysis of 22 patients who experienced neutropenia
and were either re-challenged (n=16) or maintained (n=6) on clo-
zapine and followed for a mean of 7.2 years. At the end of the ob-
servation period, only one patient stopped clozapine due to neutropenia
after the patient experienced 11 neutropenias. The results suggest that
maintaining a patient on clozapine or re-challenging the patient with
clozapine after a few months could be a useful treatment option fol-
lowing a neutropenia episode after discussing risks/benefits with the
patient and his/her family.
Alan Breier (Indiana University School of Medicine, USA) presented
findings from an eight-week randomized “add-on” study investigating
fingolimod, an anti-inflammatory agent approved for relapsing multiple
sclerosis, versus placebo in schizophrenia. The study randomized 40
subjects and found that there was no significant difference between
fingolimod and placebo in terms of cognition and symptoms. However,
there was a relationship between fingolimod-induced percent lympho-
cyte decreases and diffusion tensor imaging fractional anisotropy (DTI-
FA) increases.
Kenneth Koblan (Sunovion Pharmaceuticals, Inc., USA) discussed a
study that investigated SEP-363,856, a novel psychotropic agent with a
non-D2 mechanism of action, for the treatment of schizophrenia. SEP-
363,856 is a full agonist at TAAR1 and 5-HT1A. SEP-363,856 reduced
striatal activation in a reward processing task. Furthermore, in a 4-week
randomized, placebo-controlled trial, SEP-363,856 reduced total psy-
chotic symptoms and negative symptoms. The drug was well-tolerated
in the 4-week randomized controlled trial and in the subsequent 6-
month open label period.
Thomas Guillot (Neurocrine Biosciences, Inc, USA) discussed a
study investigating the long-term effects of valbenazine on tardive
dyskinesia in patients with schizophrenia /schizoaffective disorder.
Valbenazine is a highly selective vesicular monoamine transporter 2.
After either 42 or 48 weeks of treatment with valbenazine, participants
were recruited to be followed for an additional 72 weeks, and in this
longer follow-up period, valbenazine continued to be generally well-
tolerated with high rates of patient satisfaction and improvements in
tardive dyskinesia symptoms.
Matthijs Bossong (University Medical Center Utrecht, Netherlands)
presented a study that found cannabidiol reduced resting state perfu-
sion in a brain network comprised of the parahippocampus, hippo-
campus, and striatum in a 3-week randomized controlled trial com-
paring placebo (n=17) with purified cannabidiol (n=16) in
individuals at clinical high risk for psychosis. While total symptom
scores decreased more with cannabidiol than placebo, the differences
were not statistically significant.
15. Genetic studies
Lynn DeLisi (VA Boston, USA) presented a historical perspective on
the genetic heritability of schizophrenia. Schizophrenia is considered a
complex non-mendelian trait, and involves multiple genetic factors, as
well as gene-environment and epistatic interactions. Initial family and
twin studies support a high heritability for the disorder (∼80%). Early
linkage studies also led to the identification of initially promising risk
genes of interest, such as dysbindin and neuregulin. Genome-Wide
Association Studies (GWAS) conducted over the last decade have
identified hundreds of other significant sites with promising leads that
do not include the earlier findings. However, some of the heritability for
schizophrenia cannot be explained only by these variants, suggesting
the involvement of rare mutations with a large effect size within some
families. Genetic testing may hold value in the near future for predic-
tion of treatment response as a promising avenue for further research,
but it is unlikely to be useful for predicting who will develop schizo-
phrenia.
The relationship between genetic factors and cognitive functioning
came under discussion. Cecilie Lemvigh (University of Copenhagen,
Denmark) conducted a twin study (N=214) to investigate the asso-
ciation between specific cognitive domains, using the Cambridge
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Neuropsychological Test Automated Battery, and genetic liability for
schizophrenia. The study findings indicate that the spatial span task,
which is a measure of working memory, is associated with genetic
liability for schizophrenia, which is independent of IQ. Giada Tripoli
(King's College London, UK) also investigated the association between
cognition and genetic factors. She examined whether the genetic risk
that someone has for schizophrenia (defined by a polygenic risk score)
is associated with facial emotion recognition, a measure of social cog-
nition. Her study included 412 individuals with a first episode of psy-
chosis and 805 healthy controls. The study findings indicate that a
higher polygenic risk score for schizophrenia is a predictor of poorer
facial emotion recognition, especially for negative emotions.
Jaana Suvisaari (National Institute for Health and Welfare, Finland)
presented ongoing work examining CCL22 and 37 other important cyto-
and chemokines in a longitudinal study. The cohort consisted of a
clinically high risk (CHR) participants (n=35), patients with a first
episode of psychosis (FEP) (n=129) and healthy controls (n=130).
The study supports elevated levels of CCL22 in FEP, additionally
showing elevated levels in CHR. Elevated CCL22 level was correlated
with symptom severity at both baseline and one-year follow-up.
Increased levels of CCL22 also correlated with almost half of the other
immune markers studied.
Johannes Vogt (Phillips-University Marburg, Germany) discussed
the role of synaptic lipid signaling (lysophosphatidic acid signaling/
LPA signaling) in neuropsychiatric disorders specifically in the context
of schizophrenia. He and his team utilized electron microscopy, cell
culture experiments, mass spectrometry and electrophysiological ex-
periments to probe the scope and extent of synaptic LPA signaling in the
mouse model. They noted that autotaxin (ATX) is synthesized in the
astrocytic compartment, and selectively modulates excitatory but not
inhibitory synapses on glutamatergic neurons. Further, both pharma-
cological and cell-type specific genetic inhibition of ATX resulted in
rescue of hyperexcitability, and this was further demonstrated in the
ketamine model of schizophrenia where cortical hyperexcitability, hy-
perlocomotion and a reduced PPI were reversed to wild type levels. The
results point towards a novel mechanism to target with future drug
therapies that can restore excitatory inhibitory imbalance by targeting
synaptic ATX.
Inna Gaisler-Salomon (University of Haifa, Israel) presented data on
the regulation of glutamate homeostasis by neuron-astrocyte interac-
tion and its relevance to cognitive function in schizophrenia. She in-
vestigated the molecular, functional and behavioral implications of
disrupting glutamate dehydrogenase activity in the brain using mouse
models with CNS-Glud1 homozygous and heterozygous mutations. She
tested the interaction of this mutation with an environmental manip-
ulation by a stress exposure paradigm with social isolation.
Homozygous CNS-Glud1 mutant mice displayed schizophrenia relevant
phenotypes such as amphetamine induced hyperlocomotion, spatial
acquisition and reversal deficits in the water T-maze and social pre-
ference deficits. This was accompanied by astrocytic glutamate meta-
bolism deficits. These abnormalities were absent in heterozygous mice
but upon exposure to stress by adolescent social isolation, the cognitive
deficits could be recapitulated even in these mice.
Sinead O'Donovan (University of Toledo, USA) reported on cell type
specific alterations in adenosine generating pathways in schizophrenia.
She investigated the adenosine hypothesis in enriched populations of
pyramidal neurons and enriched populations of astrocytes from the
dorsolateral prefrontal cortex of schizophrenia subjects and corre-
sponding controls (n=16/group). The effects of chronic antipsychotic
exposure in the postmortem sample were controlled for by examining
gene expression patterns in haloperidol-decanoate treated rats. No
change was found in adenosine kinase gene or protein expression,
considered a key regulator of extracellular adenosine levels. However,
genes involved in extracellular adenosine-generation were significantly
altered in a cell-specific manner (ENTPD1 and 2 in astrocytes, ENT1
and adenosine receptor A1 in pyramidal neurons). A1 receptor
expression changes may be driven by antipsychotic exposure. The re-
sults provided new insights into the role of adenosine hypofunction in
schizophrenia.
Philip Haydon (Tufts University, USA) presented in vitro and in vivo
work suggesting that NMDA receptor hypofunction in schizophrenia
may be related to diminished activity of the α7-nAChR that is expressed
on astrocytes in the hippocampus. His work explored the role of as-
trocyte in synapse modulation mainly during sleep. This modulation
seems to be NMDAR/D‑serine-dependent according to time of the day
and darkness. NMDAR co-agonist site saturates during the dark phase
(active phase) – endogenous d‑serine decreases. Nicotinic receptors are
particularly important in astrocytes: optogenetic stimulation of choli-
nergic fibers causes an alfa-7 dependent increase in occupancy of co-
agonist site of NMDAR, but neuronal alfa7 are not required for choli-
nergic control of NMDAR co-agonist. He found that deletion of astro-
cytic alfa7 nicotinic receptor leads to reduced hippocampal d‑serine in
male mice, but not in female. The findings may guide strategies for
using medications that stimulate the α7-nAChR to normalize NMDA
receptor function in schizophrenia. Similarly, Anthony Grace
(University of Pittsburgh, USA) presented data from animal studies of a
developmental disruption model of schizophrenia that support aberrant
activity of the α7-nAChR, as well as the ability of novel classes of α7-
nAChR-modulating drugs acting in the hippocampus to reverse the
hyperdopaminergic tone. His presentation focused on the MAM devel-
opmental model of schizophrenia that is based on the dopamine hyper-
responsivity hypothesis of schizophrenia. Compared to control rats,
MAM rats had significantly increased number of active DA neurons in
the ventral tegmental area driven by an overactive hippocampus. Both
full and partial agonists reduced the hyperdopaminergic state in MAM
rodents compared to controls This is a novel finding suggesting the
potential of alpha 7 receptors as a therapeutic target for schizophrenia.
Then, Jennifer Coughlin (Johns Hopkins University, USA) presented
in vivo imaging findings using [18F]ASEM PET in patients with recent
onset of psychosis. In this study, [18F]ASEM with positron emission
tomography (PET) was used to test for low in vivo availability of the
hippocampal α7-nAChR in individuals with recent onset psychosis
compared to healthy controls (HC). Results showed that, among pa-
tients with recent onset psychosis, hippocampal [18F]ASEM binding
(total distribution volume) was lower in comparison to controls. Among
patients, higher hippocampal [18F]ASEM binding was associated with
better verbal memory and processing speed.
Sharon Hunter (University of Colorado, USA) presented data from a
recent clinical study probing preventative pharmacologic strategies
targeting cholinergic signaling in psychosis. In a double blind rando-
mized control design, 100 pregnant women were given 900mg of
choline or corn oil daily and for 3 months, the infants received 100mg
of choline. At 4 weeks of age, supplemented infants had better cerebral
inhibition with P50, which was true even for infants with increased
genetic risk. It was also noted that the males responded better than the
females to choline supplementation. She emphasized the importance of
increasing the choline levels in maternal diet, treating maternal mental
health conditions like anxiety and depression, and abstinence from
nicotine and cannabis, to help preserve normal development.
Kiran Girdhar (Mt Sinai, USA) presented research on differential
histone medication in schizophrenia patients (n=250) compared to
controls (n=330). Differential binding of enhancer regions were evi-
dent between the two groups. Pathway analysis further showed en-
richment in enhancer regions for potassium and calcium channels.
There was also significant enrichment for genome-wide association
study loci for differentially modified enhancer regions.
Victoria Rodriguez (King's College London, UK) presented findings
from a study, which explored whether a polygenic risk score for schi-
zophrenia, bipolar disorder and depression can distinguish between
diagnostic categories for affective psychosis. Both the polygenic risk
score for schizophrenia and bipolar disorder effectively distinguished
between non-affective psychosis and bipolar disorder compared to
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controls, whereas only the bipolar polygenic score was able to distin-
guish psychotic depression versus controls. The schizophrenia poly-
genic risk score could further distinguish between affective and non-
affective psychosis and, within the former, between bipolar psychosis
and psychotic depression.
Guillo Pergoa (University of Bari Aldo Moro, Italy) presented results
from a study, which compared the neurophysiological correlates of
polygenic risk and co-expression (miR-137 network translation). Co-
expressed genes were associated with miR-137, which was involved
with working memory and emotional face processing. A polygenic co-
expression index was developed to predict treatment response to
olanzapine in patients.
16. Negative symptoms
Dawn Velligan (University of Texas Health Science Centre at San
Antonio, School of Medicine, USA) reviewed the literature on the
Motivation and Engagement (MOVE) program, which consists of dif-
ferent therapeutic components to improve negative symptom domains
and functioning. She highlighted that psychosocial interventions, such
as MOVE are associated with improvement in only certain domains, but
not all domains.
Jason Holden (University of California, San Diego, USA) presented a
novel intervention for negative symptoms in schizophrenia, called the
Mobile-assisted Cognitive Behavioural Therapy for Negative Symptoms
(mCBTn), which combines Cognitive-Behavioral Social Skills Training
and a smartphone intervention (“CBT2go” application). He conducted a
study to determine whether weekly group CBT sessions paired with the
CBT2go application could reduce defeatist attitudes. Results show sig-
nificant reductions in both defeatist beliefs and motivational negative
symptoms over time (up to 24 weeks) in comparison to baseline, with
medium to large effect sizes.
Melanie Bennett (University of Maryland School of Medicine, USA)
presented on the topic of enhancing community functioning in veterans
with schizophrenia. Results were presented from an ongoing rando-
mized clinical trial of a behavioral intervention to increase community
engagement across three centers, called Engaging in Community Roles
and Experiences (EnCoRE). To date, 108 veterans with schizophrenia
spectrum disorders and negative symptoms have enrolled. Taken to-
gether, participants were positive about the program and in particular
about the benefits of action planning and social skills training. Those
who attended more often reported more frequent use of EnCoRE skills
and strategies to increase participation in community activities.
Participants reported doing more activities that they found enjoyable,
and there was some suggestion that people continued this after the
program ended.
Felice Reddy (VA Greater Los Angeles, USA) presented a study that
used an intervention consisting of Motivational Interviewing (MI) and
cognitive behavioural therapy (CBT) interventions for the treatment of
negative symptoms. She randomized veterans with schizophrenia and
negative symptoms to 12 weeks of either group-based MI+CBT for
negative symptoms (treatment arm) or a mindfulness skills training
group (control arm). Participants in the treatment arm showed im-
proved motivational negative symptom scores. However, no changes
have been observed on the defeatist beliefs or community functioning
measures, though this may be due to the behavioral focus of the in-
tervention, or its length.
Thomas Pollak (Institute of Psychiatry, Psychology & Neuroscience,
King's College London) examined plasma samples from individuals at
clinical high risk (CHR) for psychosis and healthy controls and found
toxoplasma exposure was related to severity of negative symptoms and
poor functional outcomes in CHR individuals. Moreover, he suggested
Epstein-Barr virus (EBV) exposure could be a protective factor for de-
veloping psychosis.
Anthony Ahmed (Weill Cornell Medical College New York
Presbyterian Hospital, USA) critiqued the two dimensional model of
negative symptoms. According this model symptoms are categorized
into either diminished expressions or anticipated experience of emo-
tions. Instead he proposed that a five factor model is more appropriate.
Together with his colleagues he conducted a serious of studies, which
included a factor analysis examining the latent structure of negative
symptoms from the Scale for the Assessment for Negative Symptoms
(SANS), Brief Negative Symptom Scale (BNSS), and Clinical Assessment
Inventory for Negative Symptoms (CAINS), as well as a network ana-
lysis, which was applied to examine the latent structure of negative
symptoms in American and Italian outpatients rated on the BNSS. The
findings provide support for a five-factor structure model, including
emotional blunting, anhedonia, asociality, avolition and alogia.
17. Psychosis among migrants and minorities
Brian O'Donoghue (Orygen, the National Centre of Excellence in
Youth Mental Health, Australia) investigated whether migrants have an
increased risk of developing a first episode of psychosis (FEP) and
transitioning to a full psychotic disorder. Data included records from
individuals aged 15–24 years with a FEP who presented to an early
psychosis centre in Melbourne between 2011–2013 (N > 700), and
records from a cohort of young people identified as ultra-high risk (N >
400). Overall, there was no significant difference in risk of psychosis for
migrants as a total group. However, migrants from North and Middle
East Africa and Sub-Saharan Africa showed increased risk of developing
a FEP compared to individuals born in Australia. In contrast, migrants
from Asia showed decreased risk of developing a FEP compared to
natives. First-generation migrants were under-represented in the ultra-
high risk cohort, suggesting that they are less likely to attend ultra-high
risk clinics. With regard to transitioning, data was pooled from other
groups (N > 2000), revealing no difference in the rate of transition for
migrants versus those born in Australia. Thus, particular migrant
groups in Australia have increased risk of developing a FEP but are
under-represented in ultra-high risk clinics.
Els van der Ven (Columbia University, USA) presented data in-
vestigating the risk of psychotic disorder in first- and second-generation
immigrants across urban and rural areas in different host countries.
Incidence rates were analyzed from individuals with a first episode of
nonorganic psychosis from the European Network of National
Schizophrenia Networks Studying Gene-Environment Interactions (EU-
GEI) study, including 19 centres across Europe (N > 1500). Overall,
there was a higher incidence of psychotic disorders among non-Western
migrant groups in Europe. Regions with greater overall incidence also
had a higher incidence rate among migrants, including London,
Amsterdam, Paris, and Creteil. The relative risk between sites was quite
variable, with almost a seven-fold increase in variation in migrants.
These results indicate that among migrants and their descendants there
is large variation in the incidence of psychosis across regions, sug-
gesting that not only region of origin, but also region of destination,
confers psychosis risk.
Kelly Anderson (Western University, Canada) presented work in-
vestigating whether there are differences across ethnic minority groups
in hospitalization and involuntary admission after psychosis onset, and
whether there are symptom and behavior differences between groups.
Migrant groups had increased rates of hospitalization and involuntary
admission in comparison to a general population reference group, aside
from migrants from Latin America. Further, the rates of involuntary
admission were slightly higher in refugee groups. Elevated risk of in-
voluntary admission was also seen in African and Caribbean im-
migrants, and Caribbean refugees in particular, in comparison to im-
migrants from Europe. Lastly, migrants were more likely to be
perceived as being more aggressive and posing a risk of harm to others
than the general population. Thus, migrant status confers greater risk of
involuntary admission, and migrant groups show different clinical
presentation, or are at least perceived to. However, adjusting for dif-
ferences in clinical presentation did not negate the relationship between
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migrant status and involuntary admission, suggesting that this is not
driven by clinical presentation alone.
Oladunni Oluwoye (Washington State University, Spokane, USA)
presented work on racial and ethnic differences in psychiatric symp-
toms and service utilization in participants enrolled in the multi-center
Recovery After An Initial Schizophrenia Episode – Early Treatment
Program (RAISE-ETP) for first-episode psychosis. Seventeen sites were
randomized into usual community care (N=181) and 17 to NAVIGATE
(N=223), a coordinated specialty care model for first episode psy-
chosis. In the community care group, non-Hispanic Black participants
were less likely to receive individual therapy than non-Hispanic white
participants, and Hispanic families were less likely to receive family
psychoeducation than non-Hispanic white families. Within NAVIGATE,
non-Hispanic Black participants were less likely to receive family psy-
choeducation than non-Hispanic white participants. Among non-
Hispanic Black participants, those with family involvement at baseline
had better quality of life across the 24-month treatment period, though
this was not the case in non-Hispanic white participants. These results
suggest that non-Hispanic Black individuals are less likely to receive
some services in community care in comparison to non-Hispanic white
individuals. Further, non-Hispanic black families are less likely to re-
ceive family psychoeducation, and this lack of family engagement ne-
gatively impacts quality of life outcomes. Thus, identifying cultural
barriers to treatment engagement for those experiencing their first
episode of psychosis needs further investigation.
18. The early identification and prevention of psychosis
Lotta-Katrin Pries (Maastricht University, Netherlands) reported on
the low 6-year incidence (0.3%−0.9%) and transition (0.1%−1.2%)
rates in low-, moderate- and high-risk general population subgroups in
the Netherlands Mental Health Survey and Incidence Study (NEMESIS)
sample (n=6071). Although 49% of all cases in the high-risk group
could have been prevented if the risk had been eliminated, the lower
incidence (0.5%) and transition (1.2%) rates in this group still suggest
that only small benefits can be expected from preventive approaches. A
striking observation was the high prevalence of affective symptoms
across all risk groups (75%−97%), once again underlining the multi-
dimensional nature of psychopathology in individuals at risk of psy-
chosis.
Philip McGuire (King's College London, UK) addressed whether the
North American Prodrome Longitudinal Study (NAPLS) risk calculator
can be applied to the European Network of National Schizophrenia
Networks Studying Gene Environment Interactions (EU-GEI) data.
Unlike NAPLS, however, EU-GEI verbal learning and social function
measures were not significantly associated with psychosis risk, al-
though the direction of the associations was similar to those in the
NAPLS cohort. He concluded that the NAPLS RISK calculator can not be
applied directly to EU-GEI data yet, due to differences in outcome
measures between the two studies. However, harmonized initiatives
such could aid the development of a risk calculator that can be used in
both Europe and North America.
Treatment for at risk individuals was a much-contested topic at the
congress. Alison Yung (Orygen Youth Health Research Centre,
Australia) presented a historical review and analysis of the literature to
examine ethical and practical issues in early intervention for psychosis.
She explained that there are difficulties with ultra-high risk (UHR)
identification, as the UHR threshold is an arbitrary line. Therefore, the
treatment of UHR individuals including detection, service issues, com-
munication, intervention, and whether UHR criteria are valid remains
in question. Mark Weiser (Sheba Medical Center At Tel Hashomer,
Israel) presented on the risk-benefit ratio of antipsychotic treatment in
the prodromal phase. In recent years second generation antipsychotics
have proven to have many more side effects than was previously ap-
preciated. However, the initial estimate of a 40% conversion rate in
high risk groups have fallen to around 10%. The stigma of being labeled
as having a high risk of developing schizophrenia added to the in-
creasing concern of the ethical implications of early diagnosis and
pharmacological intervention in high risk groups further complicates
matters. Cognitive behavioral therapy (CBT) as well as Omega-3-fatty
acid supplementation, was raised as a suitable alternative for early in-
tervention in psychiatry. It was argued that CBT could help bolster
resilience in those at high risk for significant mental illness. Even
though conversion to schizophrenia is quite rare, 90% of high-risk pa-
tients are likely to develop some form of mental illness worth following
up. Diana Perkins (University of North Carolina At Chapel Hill, USA)
conducted a review of the literature as well as government registries for
the current status of early pharmacological and psychotherapeutic in-
tervention. The results of the meta-analyses conclude that there is in-
sufficient evidence to support any particular intervention at present.
Several clinical trials are underway to examine the effects of specific
pharmacological treatments, psychotherapies, and a stepped-approach
to care. The psychosis clinical high-risk syndrome is not yet fully re-
cognized by standard diagnostic systems used by clinicians to document
medical services. Currently there exist little agreed-upon diagnostic
categories for attenuated psychosis, as well as evidence-based treatment
guidelines. This makes the communication of diagnostic and treatment
uncertainties in high-risk patients very difficult and ethically challen-
ging. Robert Freedman (University of Colorado Health Sciences Center,
USA) presented work on docosahexaenoic acid (DHA) and choline as
prenatal nutrients to prevent mental illnesses. A key ethical issue with
large-scale supplementation is balancing the effectiveness of the nu-
trient with cost as well as potential side-effects for the population at
large. Studies are challenging because results will not be known for
decades. Nevertheless, for prenatal choline, positive effects on cogni-
tion have been recorded as long as 7 years after birth. The AMA now
recommends evidence-based amounts of choline along with folic acid
and Vitamins A and D for all pregnant women. Accordingly, new pla-
cebo-controlled randomized trials of these micronutrients would de-
prive women of standard prenatal care. Panel members were in
agreement that an ethical trial design would offer all women supple-
ments and record maternal levels during pregnancy as the key inter-
vention variable, rather than treating some women with placebo. Fetal
developmental problems may not inevitably presage mental illness, but
neither can later interventions reverse these early defects. Therefore,
improving prenatal prevention has its own ethical imperative. The
discussant, William Carpenter (University of Maryland School of
Medicine, USA) concluded that the use of antipsychotics in clinical high
risk patients remain unresolved. Psychotic like experiences are ubi-
quitous in clinical high risk, but symptoms of full psychosis emerge in a
minority of cases. Concerns have been expressed that CHR includes
false positive cases for psychosis and may lead to excessive AP drug
treatment. But the CHR construct identifies persons who merit clinical
care [no false positives] only some of whom progress to full
psychosis. Patients are treated according to their presenting problems,
not their diagnosis. CHR is associate with potential progression to full
psychosis. Risk calculators contribute to estimate of risk at the outset
and clinicians are further informed if psychotic-like symptoms progress
over time. He suggests that we move away from trying to predict the
development of a specific diagnosis, and rather focus on more general
presentations along a spectrum of potential
psychopathology. Diagnostic class will be clarified over time and CHR
as defined by the Attenuated Psychosis Syndrome in Section 3 of DSM-5
serves as a placeholder diagnostic category.
19. Language impairments
Alban Voppel (UMC Groningen, Netherlands) presented findings on
speech measures in a schizophrenia cohort, both as a central symptom
and as a side-effect of antipsychotics. Patients with schizophrenia were
divided in high versus low DA2 receptor efficacy groups, controlling for
dosage. A relatively short semi-structured interview was used with the
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purpose of speech elicitation. Transcription and editing were performed
and the results obtained confirm that pathological speech is also in-
fluenced by medication: D2R occupancy of medication has a significant
effect on speech measures. Semantic incoherence of speech was com-
puted using word2vec comparing healthy controls with the schizo-
phrenia cohort; measures of coherence showed significant differences,
usable for classification, conforming the utility of automatic linguistic
analysis to measure pathological speech, a main feature of schizo-
phrenia.
Elkin Gutierrez (IBM Research, USA) presented on an algorithm that
was used to identify metaphoricity of individual words within a sen-
tence. This was then applied to speech produced by patients based on
open-ended interviews. The results showed that metaphoricity for free
speech was higher in clinical high-risk (CHR) individuals and patients
with schizophrenia than healthy controls. Metaphoricity was not ex-
plained by bizarreness or sentiment coherence. These findings confirm
increased production of metaphoricity in free speech. Additionally, they
suggest the putative role of metaphoricity in the identification of an
individual as CHR.
Natália Mota (Brain Institute at Federal University of Rio Grande do
Norte, Brazil) presented on the use of graph theory to measure thought
disorganisation through graph analysis of dream reports. The results
evidenced fragmented speech in patients with schizophrenia, as well as
fewer words and smaller connected components when talking about a
dream or affective images compared to other subjects, but not when
talking about daily life events. Furthermore, speech connectedness
correlated with negative symptoms and with brain dysconnectivity.
Terje Holmlund (University of Tromsø, Norway) discussed the re-
levance of using technological advances in the form of smart devices as
an effective and affordable way to monitor clinical events. A mobile
tool was developed to enable participants to remotely self-administer
daily interactions through a smart device. The analysis of speech sam-
ples revealed that it was possible to detect abnormalities in the struc-
ture of language in schizophrenia. The results also show that new
technologies provide unprecedented opportunities for remotely mon-
itoring behavior.
Eric Tan (Swinburne University, Australia) points out that abnormal
speech patterns are prevalent in individuals with schizophrenia and in
combination with machine learning could potentially be used as an
objective diagnostic marker for the disorder. It was found that in
comparison to healthy controls, schizophrenia patients surprisingly had
more utterances per minute. He used machine learning to successfully
differentiate patients from controls based on the number of word re-
visions, words used per minute, and the number of utterances with
omissions.
20. Sensory processing
Various presenters focused on visual processing impairments in
their talks. Brian Keane (Rutgers University, USA) proposed that visual
shape completion could potentially serve as a useful biomarker in
schizophrenia. He based this on a study assessing shape completion in
schizophrenia patients. The study found equivalently impaired visual
shape completion in first episode and chronic patients, suggesting that
this abnormality could potentially be a fixed trait at the time of the
diagnosis. Patients also had impaired shape completion compared to
bipolar disorder patients, indicating that the effect is relatively illness
specific. The deficit is additionally linked to cognitive disorganization
and poor premorbid functioning. All patient groups showed normal
responses to alterations in illusory contour salience, suggesting that
patients can form illusory contours, but not utilize them to discriminate
shapes. In summary, visual shape completion is worse in schizophrenia,
present at illness onset, with large effect sizes (>0.8), not explained by
attention, motivation, and broad orientation tuning, which implicates
later processing stages: i.e. individuals diagnosed with schizophrenia
form illusory lines, but do not properly use them perhaps because of
impairments to higher-order cognition. Scott Sponheim (University of
Minnesota, USA) presented data from two experiments. One, a com-
bined magnetoencephalography MEG/ functional imaging study in
schizophrenia, examining brain responses while participants detected
contours made up of visual elements, surrounded by a dense field of
similar elements. The findings indicate that during contour perception
there was diminished MEG response. A second study examined these
disturbances in a combined group of schizophrenia patients, first degree
relatives of schizophrenia patients, as well as healthy controls. The
study investigated object perception and neural timing and found
anomalies in N400, which is associated with identifying objects. The
study suggests that the initial registration of visual stimuli could be the
core feature of visual disturbances in schizophrenia. Diminished effects
of perceptual context during contour detection may reflect genetic
liability for schizophrenia and is apparent in biological relatives of in-
dividuals with this disorder. Ivy Tso (University of Michigan Medical
School, USA) presented data on the role of altered gaze perception
processing in schizophrenia. The study involved a group of 47 schizo-
phrenia and 55 bipolar patients, with 55 healthy controls. Participants
were shown faces with varying gaze directions and asked whether they
were making eye contact with the participant. The slope and absolute
threshold of the perception curve were used as indices. The study re-
vealed reduced perceptual sensitivity as well as an increased self-re-
ferential bias for both patient groups. Although schizophrenia tended to
have more severe abnormalities on average than bipolar disorder, dif-
ferences were not statistically different. Effective connectivity analysis
suggests a primary dysfunction of the visual cortex, with aberrant top-
down processes compensatory in nature. Antigona Martinez (Nathan S.
Kline Institute of Psychiatry, USA) used a motion detection task to study
visual processing in patients with schizophrenia and autism. Both pa-
tient groups showed impaired motion sensitivity and face emotion re-
cognition. Visual processing deficits were associated with distinct
neural responses in each group: while schizophrenia patients demon-
strated deficient neural response, autism patients demonstrated ele-
vated neural response during motion processing. Steven Silverstein
(Rutgers University, USA) used electroretinography (in which flashes of
light of various intensities, colors, and frequencies are presented to the
center of the eye) to examine retinal processing abnormalities in schi-
zophrenia patients. Compared to a group of age- and sex-matched
psychiatrically healthy control subjects, people with schizophrenia
showed deficient retinal processing at higher light intensities, but not at
lower intensities, suggesting that they may have difficulty accurately
representing stimulus changes as intensities increase. In contrast, defi-
cits were not detected in a comparison group of patients with major
depressive disorder.
Caitlyn Kruiper (University Medical Center Utrecht, Netherlands)
studied the relationship between sensory gating and cognitive frag-
mentation in an antipsychotic naïve, first-episode schizophrenia cohort.
Sensory gating is the pre-attentive automatic process whereby irrele-
vant sensory information is filtered out, saving processing resources for
more salient inputs. She did not find strong evidence supporting a re-
lationship between sensory gating and poor cognition. However, sen-
sory gating was associated with general symptomatology.
Jason Johannesen (Yale University School of Medicine, USA) pre-
sented three separate studies examining the psychometric, functional
and neurophysiological correlates of social attribution task-multiple
choice (SAT-MC) performance in schizophrenia. The first study ex-
amined the psychometric properties of the SAT-MC compared to stan-
dard video based cognitive tests in a group of schizophrenia patients as
well as patients with a substance use disorder. The second study ex-
amined functional relationships of the SAT-MC and affect recognition
(BLERT) performance across neurocognitive, metacognitive, theory of
mind (ToM), and symptom domains in 72 adults with schizophrenia.
Lastly, in an ongoing study, an adapted version of the SAT-MC was used
to study neurophysiological correlates using EEG in a group of chronic
SZ patients, clinically high-risk patients as well as matched healthy
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volunteers. It was found across studies that the SAT-MC has good
construct validity and diagnostic specificity for schizophrenia, and
correlates with processes outside that of the visual modality, such as
memory encoding and emotional intelligence. Preliminary psychophy-
siological findings implicate occipital gamma-band desynchronization
as a candidate mechanism of animacy perception. It was concluded that
the SAT-MC, and associated visual science construct of animacy per-
ception, capture a core aspect of social cognitive difficulties in schizo-
phrenia characterized by failure to integrate primary perceptual pro-
cesses with top-down interpretative abilities.
Studies relating to the theme of auditory processing deficits were
presented. Alice Medalia (Columbia University, USA) tested whether
the presence of early auditory processing (EAP) deficits can be used to
personalize cognitive remediation (CR) of schizophrenia patients.
Patients with baseline EAP deficits made significantly more cognitive
gains when CR included EAP training, while patients without EAP
deficits showed no benefit from EAP training. These findings suggest
that EAP treatment is only indicated in people with identified EAP
deficits and that EAP should be assessed at baseline to personalize CR.
Amanda Mccleery (University of California, Los Angeles, USA) used a
mismatch negativity (MMN) task to study predictive coding in schizo-
phrenia patients. Patients with auditory hallucinations, but not non-
hallucinators, showed impaired MMN. These findings suggest halluci-
nations may be associated with deficits in prediction signaling related
to noisy or aberrant sensory processing. Julien Laloyaux (University of
Bergen, Norway) reported on work that explored the role played by
noise frequencies and expectations on the elicitation of false percep-
tions using white noise in people with auditory hallucinations (AH).
They selected hallucination-prone and non-prone subjects, among un-
dergraduate students to perform a semantic signal detection task
varying the level of expectation associated with the perception of a
word and as well as the frequencies of the noise presented during the
task. In conclusion, the study found that false perceptions in the white
noise paradigm in people with AH are driven by both: (i) specific fre-
quencies contained in the white noise and (ii) a high level of expecta-
tion. These results support the latest cognitive models of AH that claim
that AH arise from an interaction between top-down and bottom-up
cognitive mechanisms. Ann Shinn (McLean Hospital, USA) explored
auditory hallucinations across the psychosis spectrum: evidence of
cerebellar dysconnectivity. She aimed to investigate whole-brain
resting state functional connectivity abnormalities associated with
lifetime auditory hallucinations in patients across the psychosis spec-
trum. The results suggest that aberrant cerebellar connectivity may be a
feature of auditory hallucinations (1) across the spectrum of psychosis,
(2) in schizophrenia, and (3) in bipolar disorder with psychotic fea-
tures. The findings also suggest that auditory hallucinations in schizo-
phrenia and bipolar disorder can be distinguished by differences in the
direction of cerebello-temporal connectivity. Katharina Stegmayer's
(University of Bern, Switzerland) discussed a study on auditory verbal
hallucinations with emotional content in schizophrenia. The study in-
cluded 88 participants with auditory verbal hallucinations AVH
(n=33), non-AVH (n=15), and controls (n=40). It was found that
patients with AVH had increased perfusion within the left superior
temporal gyrus compared to non-AVH patients and healthy controls.
The results suggest that AVH is linked to a dysfunction of basic lan-
guage areas. Marek Kubicki (Harvard Medical School, USA) in-
vestigated the association between microstructural white matter ab-
normalities and auditory verbal hallucinations. In this study, 23 chronic
schizophrenia subjects (mean duration of illness 16.5 years) and 23
matched healthy controls were included. The study used FreeSurfer
parcellations for tractography seeding. Stochastic tractography method
was used for generating tracts. Fractional anisotropy was calculated and
averaged over the tracts separately for dorsal and ventral connections.
The results suggested that schizophrenia is associated with white matter
pathology. Their results also pointed out that myelin abnormalities
likely account for the findings. Moreover, it showed that white matter
myelin pathology could lead to decreased connectivity.
21. Physical health, aging and mortality
Several talks focused on physical health and lifestyle interventions
aimed at individuals living with a serious mental illness. Leopoldo J.
Cabassa (Washington University in St. Louis, USA) presented results
from a qualitative study assessing client's experiences of a peer-led
healthy lifestyle program. A subset of participants who completed the
lifestyle program reported that the program enhanced their insight into
a healthy lifestyle and self-reported behavioral changes in terms of diet
and exercise. Additionally, clinically significant improvements in
weight-loss (23.8%), cardiorespiratory fitness 32.8%) and CVD risk
reduction (45.8%) were reported in this group of participants. Benjamin
Druss (Emory University, USA) presented two mobile health (mHealth)
studies assessing the use of mobile devices to promote physical health
in people with SMI. The first study was a randomized trial of a mobile
personal health record for individuals with SMI and medical co-
morbidity, and the second was a trial of differing forms of financial
incentives coupled with wearable devices to increase physical activity
among inactive individuals with SMI. The study findings suggested that
mHealth can be used to support improvements in quality of care and
health behaviors in SMI. Kelly Aschbrenner (Department Of Psychiatry,
Geisel School of Medicine at Dartmouth College, USA) presented an
overview of a study protocol and baseline data for a randomized con-
trolled trial evaluating the effectiveness of a peer group lifestyle in-
tervention enhanced with mobile health technology to address cardio-
metabolic risk in young adults with serious mental illness. Her
presentation included a review of studies on evidence-based lifestyle
interventions for individuals with a serious mental illness (SMI).
Findings suggest that modifications may need to be made to existing
interventions to meet the needs of young mental health service users,
including peer support and use of popular technologies to support
health behavior change to improve health in this group. Nuray Çakici
(Academic Medical Center, Amsterdam) conducted a meta-analysis on
blood compounds in drug-naïve first-episode schizophrenia and de-
pression, and identified similar changes in growth, immune and glucose
factors in both disorders. These findings might indicate shared pre-
ventive strategies and treatment for immune and metabolic dysfunc-
tions present in the early illness course in both the disorder types.
Martin Strassnig (University of Miami, USA) presented ecological mo-
mentary assessment data on sedentary behavior in people with schi-
zophrenia (n=100) and healthy controls (n=71). A consistent picture
emerged in people with schizophrenia, namely they completed more
surveys at home, were less likely to be in the company of others, and
spent the majority of time on sedentary activities (for example,
watching television, resting and/or smoking). The results highlight the
lack of daily activity patterns in people with schizophrenia, and un-
derline the need for exercise-focused interventions.
The topic of accelerated aging in schizophrenia emerged during the
congress. Brian Kirkpatrick (University of Nevada School of Medicine,
USA) discussed the history and current knowledge on accelerated aging
associated with schizophrenia. He focused in his talk on how develop-
ments in molecular technologies and neuroimaging can support further
research aimed at exploring the roles of oxidative stress, impaired
glucose tolerance, and inflammation on brain age in schizophrenia
patients. He emphasized that genomic testing in particular has con-
sistently identified a strong correlation between DNA epigenetic me-
thylation and biological age in schizophrenia populations. He also
noted the importance of considering previous confounds including an-
tipsychotic exposure, dietary habits and body mass index when ex-
ploring accelerated aging in schizophrenia. Leticia S. Czepielewski
(Universidade Federal do Rio Grande do Sul, Brazil) presented a study
investigating the role of telomere length as a proposed marker for ac-
celerated aging in schizophrenia. In addition, the study considered the
effects of CCL-11 levels as a marker of inflammation on telomere length,
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global gray matter volume, and verbal episodic memory performance.
In this study, schizophrenia patients had decreased telomere length
compared to unaffected individuals, which was associated with higher
inflammation, poorer verbal episodic memory, and reduced gray matter
volumes in the brain. Shorter telomere length also mediated the dele-
terious effects of longer illness duration on verbal memory, which was
also correlated with higher inflammation. Igor Nenadic (Philipps-
Universität Marburg, Germany) presented work done on the influence
of schizophrenia subtype on the association between actual age and
estimated brain age assessed from a T1 brain scan using a machine
learning tool. The findings suggest brain age differences between con-
trols and two patient groups, namely first-episode schizophrenia pa-
tients, and those at ultra-high risk for psychosis. Importantly, the same
was not found in a cohort of bipolar disorder patients. Julia Sheffield
(Vanderbilt University Medical Center, USA) proposed that accelerating
aging and associated changes in connectivity of the cingulo-opercular
and fronto-parietal networks are characteristic of psychotic disorders.
She identified reduced global efficiency of these networks, known to be
implicated in higher-order cognitive functioning, in patients with
chronic psychotic disorders, but not first-episode patients. The findings
suggest that the connectivity of these networks is preserved in first-
episode psychosis, but markedly reduced in patients with chronic ill-
ness. Tamsyn Van Rheenen (University of Melbourne, Australia) pre-
sented a study investigating age-related changes in fluid reasoning,
working memory, frontal brain volume and its relationship with cog-
nitive reserve in patients with schizophrenia. Patients, when compared
to controls and considered as a whole group, had increased age-related
reductions in brain volume, but there were no significant between
group differences in age-related change of fluid cognition. Age-related
decline in fluid cognition was evident in patients with low cognitive
reserve, but there was no difference in age-related brain volume change
between patients with high or low cognitive reserve. This suggests that
higher cognitive reserve in a subgroup of schizophrenia patients buffers
against ageing effects on fluid cognition by protecting against patho-
logically exaggerated brain volume deterioration.
Elias Mouchlianitis (Institute of Psychiatry, Psychology, &
Neuroscience at King's College London, UK) presented a study in-
vestigating the association between glutamate and neurostructural in-
tegrity in patients with treatment-resistant schizophrenia. The findings
suggest that there is a significant positive correlation between anterior
cingulate cortex Glu/Cre and brain-PAD only for the treatment-resistant
patients (P=0.014). There was no significant correlation for the
treatment-responsive group or the healthy participants. The study in-
dicates glutamate levels to be associated with accelerated brain ageing
in treatment-resistant patients.
22. Computational approaches
Albert Powers (Yale University School of Medicine, USA) presented
findings from a study that used a conditioning paradigm to explore to
what extent prior beliefs about the external world dominates over
sensory information in the production of auditory hallucinations.
Participants were presented with repeated pairings of a visual stimulus
and a faintly-presented auditory stimulus during an fMRI experiment.
Participants were asked to report whether the auditory stimulus was
present when the visual stimulus was presented. Patients with psychosis
with and without hallucinations were compared with healthy voice-
hearers and healthy controls. Irrespective of psychosis status, condi-
tioned hallucinations occurred more frequently, and were reported with
stronger conviction, in participants who hallucinate. Computational
modeling also showed an increased reliance on prior beliefs in those
with hallucinations irrespective of psychosis status. This suggests that
both patients and controls who experience auditory hallucinations ex-
hibit greater reliance on prior beliefs compared to incoming sensory
information. High-level model parameters encoding volatility beliefs
about the stimulus relationships discriminated between participants
with and without psychosis. Activity in anterior insula and superior
temporal sulcus encoded low-level perceptual beliefs and differentiated
hallucinating from non-hallucinating groups, while activity in para-
hippocampal gyrus and cerebellum encoded volatility beliefs and dif-
ferentiated psychotic from non-psychotic participants.
John Torous (Harvard Medical School, USA) discussed the value of
exploring smartphone data to support cognitive assessment in schizo-
phrenia patients based on the characterization of “digital fingerprints”.
He argued that digital phenotyping and collection of passive device
data could hold promise in the prediction of possible relapse in patients.
Kathryn Hess (École Polytechnique Fédérale de Lausanne,
Switzerland) presented data on the use of topological analysis to predict
functional and social outcomes in early psychosis patients (n=101)
with similar clinical and/or metabolic profiles followed up over three
years. The application of topological analysis based on baseline psy-
chopathology identified three patient groups with distinct patterns of
social and occupational outcomes. The group characterized by low le-
vels of negative and depressive symptoms at baseline had better social
and occupational functioning at follow-up and a distinct biological
profile. In contrast, the patient group with high levels of positive
symptoms at baseline showed the worst social and functional outcomes
at three years. She emphasized the value of emerging computational
techniques to predict functional outcomes in early psychosis based on
clinical and metabolic assessments at baseline.
Dominic Dwyer (Ludwig-Maximilian-University, Germany) pre-
sented a study that used a combination of clinical, imaging-based, and
combined data to predict social and role functioning in a group of
clinically high-risk (n=116) and recent-onset depression (n=120). As
part of the study, a predictive model for functional outcome with a high
sensitivity and specificity was developed. The presenter emphasized
that, while external validation of this model was necessary, it provides a
good example of how combining multi-modal data can support the
development of improved prediction models for functional outcomes in
high-risk patient groups.
23. Interdisciplinary interventions
Jimmy Choi (Olin Neuropsychiatry Research Center, USA) pre-
sented data from a study, which sought to engage schizophrenia pa-
tients with low motivation in physical exercise as part of a rehabilita-
tion program. Towards this goal, a clinical trial was conducted to
explore the efficacy of an “exergame” intervention, which combines
elements of physical activity with neurocognitive rehabilitation ex-
ercises, sometimes within a virtual reality environment. The interven-
tion resulted in an improvement in negative symptoms and working
memory in patients irrespective of their motivation. However, a sig-
nificant improvement in processing speed and positive symptoms was
only evident in the high-motivation group. Results from this study
supported the value of “exergaming” to engage schizophrenia patients
with low motivation in physical activity.
Mike Best (Queen's University, Canada) presented findings from an
open-label pilot study, which sought to explore the value of a novel
intervention for internalized stigma in first-episode psychosis patients
(n=15). The eight-session BOOST (Be Outspoken Overcoming
Stigmatizing Thoughts) group intervention took the form of brief group
treatment sessions, and combined elements of cognitive restructuring
with assertive communication skills and peer support. In this study,
BOOST was shown to improve internalized stigma, self-esteem and
global life satisfaction.
Kee-Hang Choi (Korea University, South Korea) presented findings
from a randomized controlled trial that explored the efficacy and tol-
erability of a structured psychotherapeutic approach as an adjunct to
treatment as usual in schizophrenia spectrum disorder patients.
Behavioral activation therapy consisted of a once weekly hour-long
face-to-face session conducted over ten weeks. In this study, behavioral
activation was associated with a reduction in negative symptoms post-
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treatment. However, this effect was not maintained at six-month
follow-up. Behavioral activation may offer a suitable approach to de-
creasing negative symptom severity in schizophrenia patients, although
a longer intervention period (>10 weeks) or follow-up sessions may be
necessary to maintain the beneficial effects of the intervention.
Piper Meyer-Kalos (University of Minnesota, USA) presented results
from a pilot study which explored the feasibility of Individual Coping
Awareness Therapy (I-CAT) as a means of combating stress in patients
with early schizophrenia (n=6). In this study, I-CAT improved stress
management, resilience and symptom severity, and was shown to be
both feasible and tolerable. These findings provided the basis for a
randomized controlled trial using the I-CAT in early schizophrenia,
which is currently in progress.
Jie Lisa Ji (Yale University, USA) discussed how integrating neu-
roimaging and transcriptomic data could be leveraged to inform ther-
apeutics as a part of the Gene Expression Mapping Integrated with
Neuro-Imaging for Discovery of Therapeutics (GEMINI-DOT) initiative.
As part of this initiative a study was conducted, which included 24
healthy participants. The participants were randomized to receive
placebo, lysergic acid diethylamide (LSD), or ketanserin (a 5-HT2A
receptor antagonist) and LSD. The study integrated resting-state func-
tional connectivity and gene expression data and found that whole-
brain spatial patterns of LSD effects corresponded to 5-HT2A receptor
cortical gene expression in humans, which suggests that the 5-HT2A
receptor is likely involved in LSD's neuro-pharmacology.
Jerrilyn Kent (University of Minnesota, USA) presented findings
from a study, which explored temperoparietal junction activation in
patients with psychosis (n=50) and at-risk first-degree relatives
(n=21) compared to controls (n=29) in response to an implicit
theory of mind task. In this study, temperoparietal junction activation
was lower in patients and their relatives compared to controls, sug-
gesting an association with shared genetic liability.
24. Patient adherence and engagement
Dawn Velligan (University of Texas Health Science Center at San
Antonio, School of Medicine, USA) discussed the value of engagement
focused care in schizophrenia to facilitate long-acting injectable anti-
psychotic use and medication follow through. She presented findings
suggesting that the engagement focused program promotes the appro-
priate use of long-acting injectables by targeting three stakeholder
groups; administrators, prescribers and the end users. She highlighted
the importance of focusing on engagement and recovery goals in pro-
moting medication follow through and acceptance of long-acting in-
jectable medication.
Joy Noel Baumgartner (Duke Global Health Institute, USA) pre-
sented results from a study that sought to develop a culturally appro-
priate version of the Family Psycho-education intervention for adults
living with psychotic disorders in lower- to middle-income countries. In
this study, thematic analysis was performed on qualitative data ob-
tained from interviews conducted with patients, providers, caregivers,
religious leaders, healthcare managers and government officials living
in Tanzania (n=80). The study highlighted the role and value of fa-
mily, religion, faith, and hope as important themes to consider in the
development of psycho-education interventions. An adapted interven-
tion was developed which included an orientation session and educa-
tion workshop with family members, as well as ongoing patient-relative
group sessions. This intervention differed from conventional family
psychoeducation insofar as it incorporated tailored topics and exercises
that were culturally appropriate and engaging.
Isaac Lema (Muhimbili University of Health and Allied Sciences,
Tanzania) presented findings from a mixed method study where the
research team sought to develop and test a customized adherence en-
hancement program for treatment with long-acting injectable anti-
psychotics in Tanzanian patients with a chronic psychotic disorder. The
study found that poor medication adherence was associated with
negative patient attitudes and more severe symptomatology. Findings
from this research support the potential for use of long-acting in-
jectables in chronic schizophrenia in lower- to middle-income health
settings.
Martha Sajatovic (Case Western Reserve University, USA) presented
results from a web-based survey on long-acting injectable antipsychotic
use with the goal of assessing current practice and developing appro-
priate treatment guidelines for the management of psychotic disorders.
A total of 34 research practitioners were asked about their experiences
and recommendations for selecting and treating patients with long-
acting injectables during the initiation and maintenance phases of
therapy. Respondents indicated that approximately 30% of their pa-
tients were treated with long-acting injectable antipsychotics, which
were recommended for patients with poor insight, unstable housing, a
history of violence, and social isolation. There was agreement that long-
acting injectable antipsychotics should to be used to screen for non-
adherent versus treatment-resistant patients prior to moving on to
clozapine treatment.
25. Conclusion
In summary, a broad range of topics was covered during the first
North American SIRS congress. Interesting new work was presented
investigating schizophrenia as a disorder of the self, with presenters
emphasizing that individuals living with the illness experience an
aberrant sense of agency and body ownership. Several sessions ad-
dressed potential environmental risk factors. In particular, the influence
of childhood adversity as well as the role played by neighbourhood
factors, such as violence and poverty were considered. The importance
of timing of adversity featured, with presenters emphasizing that earlier
versus later trauma exposure was associated with distinct deficits and
symptoms. Other topics included the effects of smoking and substances.
It was emphasized that tobacco smoking is not merely a means of self-
medication. Instead, the data suggest that it is associated with suicidal
behaviour and an earlier age of illness onset. The link between cannabis
use and psychosis featured prominently and it was proposed that can-
nabis use is an important predictor of relapse. Inflammation and the
disruption of the blood-brain barrier as well as the blood-gut barrier as
potential risk factors for psychosis came under the spotlight. It was
proposed that higher levels of inflammation are associated with shorter
telomere length, which is in turn associated with accelerated aging, in
schizophrenia cohorts. In terms of cognition and functioning, memory
deficits and their association with the hippocampus were highlighted. It
was suggested that treatments should target hippocampal parvalbumin
interneurons by restoring GABAergic signaling. Relating to the topic of
functionality, the use of virtual reality to assess functional capacity was
addressed. Then the role played by genetics came under discussion.
Genetic testing could play an invaluable role in the future when it
comes to the prediction of treatment response. In terms of pharmaco-
logical treatments, the development of novel antipsychotic drugs tar-
geting cognitive impairment and negative symptoms, as well as the use
of long-acting injectables were addressed. Presenters discussed the
reasons why some patients relapse despite receiving assured treatment,
i.e. long-acting injectables. The efficacy of non-pharmacological inter-
ventions was covered and in particular the efficacy of CBTp and tDCS.
In terms of moving the field forward, novel ways of early identifi-
cation of individuals living with schizophrenia spectrum disorders were
addressed. Presenters provided evidence supporting the efficacy of
using a multi-dimensional approach to identify symptoms, with some
suggesting that patterns of similar neural network activation could be
useful in identifying patients. Others also proposed that more emphasis
should be placed on biotypes, and here impaired visual processing and
language impairments could be important biomarkers. Another topic
that has gained great momentum over the past few years and that
featured prominently during the congress is that of computational ap-
proaches. A number of presenters illustrated the usefulness of
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techniques, such as machine learning and topological analysis, to
identify patients and predict functional outcomes as well as anti-
psychotic treatment response. The advantages of big data and con-
sortiums, such as ENIGMA and GWAS came under discussion.
Other equally important topics that were covered during the con-
gress include the identification and treatment of at-risk for psychosis
populations. Presenters highlighted that the diagnosis of, and identifi-
cation of effective treatment, for individuals at-risk for psychosis re-
main problematic. It was suggested that less emphasize should be
placed on diagnosis and whether individuals with attenuated psychosis
go on to develop a psychotic disorder. Instead the focus should be more
on the presenting problems of the treating at-risk individuals. Psychosis
risk in vulnerable groups, such as migrants and refugees was discussed.
However, the evidence is inconclusive as to whether or not these po-
pulations are at greater risk for psychosis. Nevertheless, the evidence
clearly suggests that immigrants and migrants are less likely to have
access to mental health services, which in itself is highly problematic.
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